Skystar Bio-pharmaceutical (SKBI) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 12, 2014	Jun. 28, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'SKBI	'	'
Entity Common Stock, Shares Outstanding	'	7,604,800	'
Entity Registrant Name	'SKYSTAR BIO-PHARMACEUTICAL CO	'	'
Entity Central Index Key	'0001076939	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$7.70

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS(USD ($))	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS:	'	'
Cash	$8,142,296	$11,321,848
Accounts receivable, net of allowance for doubtful accounts of $602,243 and $247,269, respectively	11,009,498	10,010,796
Inventories	25,903,586	22,962,209
Deposits, prepaid expenses and other receivables	2,134,163	2,839,850
Prepayments to suppliers	41,061,144	23,438,735
Loans receivable	0	1,078,827
Deferred tax assets	364,425	0
Total current assets	88,615,112	71,652,265
PROPERTY, PLANT AND EQUIPMENT, NET	28,269,155	28,867,816
CONSTRUCTION-IN-PROGRESS	9,284,947	8,691,360
OTHER ASSETS:	'	'
Long-term prepayments	4,633,614	1,050,327
Long-term prepayments for acquisitions	183,344	177,744
Intangible assets, net	5,237,255	5,319,831
Total other assets	10,054,213	6,547,902
Total assets	136,223,427	115,759,343
CURRENT LIABILITIES:	'	'
Accounts payable	3,303,531	4,017,530
Other payables and accrued expenses	6,467,605	4,374,047
Short-term loans	10,640,500	4,443,600
Deposits from customers	1,877,211	1,621,061
Taxes payable	1,315,486	1,950,757
Due to related parties	1,361,548	798,925
Total current liabilities	24,965,881	17,205,920
OTHER LIABILITIES:	'	'
Long-term loan	0	1,269,600
Deferred government grants	802,130	1,063,290
Purchase option liability	62,440	5,600
Total other liabilities	864,570	2,338,490
Total liabilities	25,830,451	19,544,410
COMMITMENTS AND CONTINGENCIES	'	'
SHAREHOLDERS' EQUITY	'	'
Preferred stock, $0.001 par value, 50,000,000 shares authorized, no Series "A" shares authorized, 48,000,000 Series "B" shares authorized, no Series "B" shares issued and outstanding	0	0
Common stock, $0.001 par value, 40,000,000 shares authorized, 7,604,800 shares issued and outstanding as of December 31, 2013 and 2012	7,605	7,605
Paid-in capital	37,631,142	37,021,085
Statutory reserves	5,952,692	5,897,298
Retained earnings	54,990,154	44,515,296
Accumulated other comprehensive income	11,811,383	8,773,649
Total shareholders' equity	110,392,976	96,214,933
Total liabilities and shareholders' equity	$136,223,427	$115,759,343

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Dec. 31, 2013	Dec. 31, 2012
Allowance for doubtful accounts	$602,243	$247,269
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	7,604,800	7,604,800
Common stock, shares outstanding	7,604,800	7,604,800
Series A Preferred Stock [Member]	'	'
Preferred stock, shares authorized	0	0
Series B Preferred Stock [Member]	'	'
Preferred stock, shares authorized	48,000,000	48,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
REVENUE, net	$42,483,716	$33,586,791
COST OF REVENUE	20,992,962	15,095,004
GROSS PROFIT	21,490,754	18,491,787
OPERATING EXPENSES:	'	'
Research and development	956,028	2,154,241
Selling expenses	3,552,878	3,040,036
General and administrative	3,968,984	4,746,529
Total operating expenses	8,477,890	9,940,806
INCOME FROM OPERATIONS	13,012,864	8,550,981
OTHER INCOME (EXPENSE):	'	'
Other income, net	48,401	458,681
Interest income	539,587	97,591
Interest expense	-612,452	-764,500
Change in fair value of purchase option liability	-56,840	37,800
Total other income (expense), net	-81,304	-170,428
INCOME BEFORE PROVISION FOR INCOME TAXES	12,931,560	8,380,553
PROVISION FOR INCOME TAXES	2,401,308	2,168,125
NET INCOME	10,530,252	6,212,428
OTHER COMPREHENSIVE INCOME :	'	'
Foreign currency translation adjustment	3,037,734	662,542
COMPREHENSIVE INCOME	$13,567,986	$6,874,970
EARNINGS PER SHARE:	'	'
Basic (in dollars per share)	$1.38	$0.83
Diluted (in dollars per share)	$1.37	$0.83
WEIGHTED AVERAGE NUMBER OF COMMON SHARES:	'	'
Basic (in shares)	7,651,640	7,471,350
Diluted (in shares)	7,656,086	7,471,350

CONSOLIDATED_STATEMENTS_OF_SHA

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Paid-In Capital [Member]	Retained Earnings Statutory Reserves [Member]	Retained Earnings Unrestricted [Member]	Accumulated Other Comprehensive Income [Member]
BALANCE at Dec. 31, 2011	$88,102,813	$7,162	$35,784,378	$5,708,135	$38,492,031	$8,111,107
BALANCE (in shares) at Dec. 31, 2011	'	7,161,919	'	'	'	'
Share issued under Share-based compensation	1,237,150	443	1,236,707	0	0	0
Share issued under Share-based compensation ( in shares)	'	442,881	'	'	'	'
Foreign currency translation	662,542	0	0	0	0	662,542
Net income	6,212,428	0	0	0	6,212,428	0
Appropriation to statutory reserves	0	0	0	189,163	-189,163	0
BALANCE at Dec. 31, 2012	96,214,933	7,605	37,021,085	5,897,298	44,515,296	8,773,649
BALANCE (in shares) at Dec. 31, 2012	'	7,604,800	'	'	'	'
Share issued under Share-based compensation	172,891	0	172,891	0	0	0
Share issued under Share-based compensation ( in shares)	'	0	'	'	'	'
Foreign currency translation	3,037,734	0	0	0	0	3,037,734
Net income	10,530,252	0	0	0	10,530,252	0
Appropriation to statutory reserves	0	0	0	55,394	-55,394	0
Contribution from a shareholder	437,166	0	437,166	'	0	0
BALANCE at Dec. 31, 2013	$110,392,976	$7,605	$37,631,142	$5,952,692	$54,990,154	$11,811,383
BALANCE (in shares) at Dec. 31, 2013	'	7,604,800	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income	$10,530,252	$6,212,428
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Depreciation	1,467,261	1,035,829
Amortization	246,896	401,114
(Reversal of) provision for doubtful accounts	342,623	-194,971
Common stock to be issued to related parties for compensation	143,549	86,162
Common stock issued under 2010 stock incentive plan	0	1,037,911
Change in fair value of warrant/purchase option liability	56,840	-37,800
Gain on disposal of property, plant and equipment	1,754	0
Deferred tax assets	-359,638	0
Change in operating assets and liabilities	'	'
Accounts receivable	-1,016,951	-6,394,244
Inventories	-2,188,799	-7,985,875
Deposits, prepaid expenses and other receivables	763,031	1,651,478
Prepayments to suppliers	-16,662,199	6,027,718
Accounts payable	-984,623	2,307,066
Other payables and accrued expenses	2,136,675	-500,127
Deferred government grants	-452,340	190,380
Deposits from customers	202,383	176,645
Taxes payable	-687,582	1,788,790
Due to related parties	1,037,488	743,755
Net cash used in operating activities	-5,423,380	6,546,259
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchases of property, plant and equipment	-19,825	-163,049
Sale of property, plant and equipment	162	0
Payments on construction-in-progress	-148,968	-393,032
Payments of long-term prepayments	-3,515,071	-358,077
Refund of long-term prepayments	0	475,950
Loans to third parties	0	-2,023,393
Collection of loans to third parties	1,098,201	1,916,651
Net cash used in investing activities	-2,585,501	-544,950
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from short-term loans	10,500,750	5,774,860
Repayment of short-term and long term loans	-5,815,800	-7,488,280
Net cash provided by (used in) financing activities	4,684,950	-1,713,420
EFFECT OF EXCHANGE RATE CHANGES ON CASH	144,379	-15,009
(DECREASE) INCREASE IN CASH	-3,179,552	4,272,880
CASH, beginning of year	11,321,848	7,048,968
CASH, end of period	8,142,296	11,321,848
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:	'	'
Cash paid for interest	644,489	647,249
Cash paid for income taxes	1,105,002	972,739
Non-cash investing and financing activities	'	'
Long-term prepayment transferred to construction-in-progress	11,502	1,004,635
Consideration for property, plant and equipment offset against due to related parties	486,427	0
Construction-in-progress transferred to property, plant and equipment	0	1,129,588
Shares issued to settle payables to related parties	$0	$199,239

ORGANIZATION

ORGANIZATION	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	Note 1 – ORGANIZATION
	Organization and description of business
	Skystar Bio-Pharmaceutical Company (“Skystar” or the “Company”) was incorporated in Nevada on September 24, 1998. Since its acquisition on November 7, 2005 of Skystar Bio-Pharmaceutical (Cayman) Holdings Co., Ltd. (“Skystar Cayman”), a Cayman Islands company, the Company has been engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. All current operations of the Company are in the People’s Republic of China (“China” or the “PRC”).
	All of the Company’s operations are carried out by its subsidiaries in China and Xi’an Tianxing Bio-Pharmaceutical Co., Limited (“Xi’an Tianxing”), a PRC joint stock company that the Company controls through contractual arrangements originally between Skystar Cayman and Xi’an Tianxing. On March 10, 2008, the Company entered into a series of agreements transferring all of the rights and obligations of Skystar Cayman under the contractual arrangements to Sida Biotechnology (Xi’an) Co., Ltd. (“Sida”), a PRC company. Sida is the wholly owned subsidiary of Fortunate Time International Limited (“Fortunate Time”), a Hong Kong company and wholly owned subsidiary of Skystar Cayman. Xi’an Tianxing also has a wholly owned subsidiary, Shanghai Siqiang Biotechnological Co., Ltd. (“Shanghai Siqiang”), a PRC company.
	On September 18, 2009, Skystar Bio-Pharmaceutical Inc. (“Skystar California”) was incorporated in California and became a wholly owned subsidiary of Skystar. On December 20, 2010, Skystar California was dissolved.
	On April 21, 2010, Kunshan Sikeda Biotechnology Co., Ltd. (“Kunshan Sikeda”) was incorporated in Kunshan, Jiangsu Province, China with a registered capital of $81,850 (RMB 500,000), of which Xi’an Tianxing and Sida each contributed $40,925 (RMB 250,000). Kunshan Sikeda is jointly owned by Xi’an Tianxing and Sida. On July 31, 2013, Kunshan Sikeda was dissolved.
	On May 7, 2010, Fortunate Time formed Skystar Biotechnology (Kunshan) Co., Limited (“Skystar Kunshan”) in Kunshan, Jiangsu Province, China with a registered capital of $15,000,000, of which $2,250,000 was paid by Fortunate Time in cash, and of which the remaining $12,750,000 is required to be invested in the future. Skystar Kunshan was formed in connection with an acquisition of assets to meet part of the registered capital requirements, and was intended to be a micro-organism manufacturing facility for the Company once the acquisition was complete. The asset acquisition was completed in September 2011.
	On August 11, 2010, Sida became the parent company of Skystar Biotechnology (Jingzhou) Co., Limited (“Skystar Jingzhou”), a company established in Jingzhou, Hubei Province, China on February 5, 2010, with registered capital of approximately $4.3 million (RMB 26,000,000) paid by Sida.
	On March 15, 2011, Xi’an Tianxing formed Xi’an Sikaida Bio-products Co., Ltd. (“Xi’an Sikaida”) with a registered capital of approximately $1,637,000 (RMB 10,000,000 ) paid by Xi’an Tianxing.
	Hereinafter, Skystar, Skystar Cayman, Fortunate Time, Sida, Xi’an Tianxing, Skystar Kunshan, Skystar Jingzhou, Shanghai Siqiang, and Xi’an Sikaida are sometimes collectively referred to as the “Company”.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of consolidation
	The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries, and its variable interest entities (“VIEs”).  All significant inter-company transactions and balances between the Company, its subsidiaries, and its VIEs have been eliminated in consolidation.
	The Company has evaluated the relationship with Xi’an Tianxing and Xi’an Tianxing’s wholly owned subsidiaries, Xi’an Sikaida and Shanghai Siqiang. As a result of the contractual arrangements which obligate Sida to absorb all of the risk of loss from Xi’an Tianxing’s activities and enable Sida to receive all of its expected residual returns, the Company is the primary beneficiary of these VIEs and thus it accounts for Xi’an Tianxing, Xi’an Sikaida and Shanghai Siqiang as VIEs under the Financial Accounting Standards Board’s (“FASB”) interpretation on consolidation of variable interest entities. Accordingly, the Company consolidates the results, assets, and liabilities of Xi’an Tianxing, Xi’an Sikaida and Shanghai Siqiang.
	Use of estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time to complete the underlying transactions. Actual results may differ from these estimates in amounts that may be material to the consolidated financial statements and accompanying notes. Significant estimates and assumptions made by the Company are used for, but not limited to the allowance for uncollectible receivables, obsolescence reserve against inventory, useful lives of property, plant and equipment and intangible assets, assumptions used in assessing impairment for long-lived assets and the fair value for derivative instruments.
	Foreign currency translation
	The Company uses the United States dollar (“U.S. dollar”) for financial reporting purposes and the Chinese Renminbi (“RMB”) as its functional currency. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency, being the primary currency of the economic environment in which their operations are conducted.
	The Company translates the subsidiaries’ and VIEs’ assets and liabilities into U.S. dollars using the applicable exchange rates prevailing at the balance sheet dates, and the statements of comprehensive income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the subsidiaries’ and VIEs’ financial statements are recorded as accumulated other comprehensive income.
	The quotation of the exchange rates does not imply free convertibility of RMB to other foreign currencies. All foreign exchange transactions continue to take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rate quoted by the People’s Bank of China.
	Approval of foreign currency payments by the People’s Bank of China or other institutions requires submitting a payment application form together with invoices, shipping documents, and signed contracts. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.
	Fair values of financial instruments
	ASC Topic 820, Fair Value Measurement and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. Certain current assets and current liabilities are financial instruments.  Management believes their carrying amounts are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and, if applicable, their current interest rates are equivalent to interest rates currently available. The three levels of valuation hierarchy are defined as follows:
		¨	Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
		¨	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
		¨	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013 and 2012:
			Carrying
			Value at		Fair Value Measurement at
			December 31,		September 30, 2013
			2013		Level 1		Level 2		Level 3
	Purchase option liability		$	62,440	$	—	$	62,440	$	—
			Carrying
			Value at		Fair Value Measurement at
			December 31,		December 31, 2012
			2012		Level 1		Level 2		Level 3
	Purchase option liability		$	5,600	$	—	$	5,600	$	—
	Below is the reconciliation for the purchase option liability:
			December 31,		December 31,
			2013		2012
	Balance, beginning of year		$	5,600	$	43,400
	Change in fair value			56,840		-37,800
	Balance, end of year		$	62,440	$	5,600
	Revenue recognition
	Revenue of the Company is primarily derived from the sales of veterinary healthcare and medical care products in China. Sales are recognized when the following four revenue criteria are met: persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable, and collectability is reasonably assured. Sales are presented net of value added tax (“VAT”). No estimated allowance for sales returns is reflected in these consolidated financial statements as sales returns historically have been insignificant.
	There are two types of sales upon which revenue is recognized:
		a.	Credit sales: revenue is recognized when the products have been delivered to the customers.
		b.	Full payment before delivery: Cash received is recorded as “deposits from customers” and revenue is recognized when the products have been delivered to the customers.
	Cash
	Cash includes currency on hand and demand deposits with banks with an original maturity of three months or less.
	Accounts receivable
	Accounts receivable are stated at cost, net of an allowance for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses, if any, resulting from the failure of customers to make required payments. The Company reviews the accounts receivable on a periodic basis and makes allowances where there is doubt as to the collectibility of individual balances. In evaluating the collectibility of individual receivable balances, the Company considers many factors, including the age of the balance, the customer’s payment history, its current credit-worthiness and current economic trends.
	Inventories
	Inventories are stated at the lower of cost as determined on a weighted-average basis, or market. Inventories include purchases and related costs incurred in bringing the inventories to their present location and condition. Management reviews inventories for obsolescence and cost in excess of net realizable value and records a write-down  against the inventory and additional cost of goods sold when the carrying value exceeds net realizable value.
	Property, plant and equipment
	Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses, if any. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs that do not improve or extend the useful lives of the assets are charged to operations as incurred, while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. Estimated useful lives of the assets are as follows:
			Estimated useful life
	Buildings and improvements		Shorter of lease
			term or 10-40 years
	Machinery and equipment		5-10 years
	Office equipment and furniture		3-10 years
	Vehicles		5-10 years
	Management assesses the carrying value of property, plant and equipment annually or more often when factors indicating impairment are present, and reduce the carrying value of such assets by the amount of the impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted) and comparing such amount to the net asset carrying value. An impairment loss, if it exists, is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. Based on its review, management believes that, as of December 31, 2013 and 2012, there was no impairment of its property, plant and equipment.
	Construction-in-progress
	Construction-in-progress includes direct costs of construction of factory buildings. Interest incurred during the period of construction, if significant, is capitalized. All other interest is expensed as incurred. Construction-in-progress is not depreciated until such time as the asset is completed and put into service.
	Intangible assets
	Land use rights — Land use rights represent the amounts paid to acquire a long-term interest to utilize the land underlying the Company’s facilities. This type of arrangement is common for the use of land in the PRC. Land use rights are amortized on the straight-line method over the contractual lease terms.  The land use right granted to the Company’s Huxian facility was for 50 years.  The land use right granted to the Company’s Jingzhou facility was 30 years. The land use right granted to the Company’s Kunshan facility was for 41 years.
	Technological know-how — Purchased technological know-how includes confidential formulas, manufacturing processes, and technical and procedural manuals, and is amortized using the straight-line method over an estimated useful life of between five to eleven years that reflects the period over which such confidential formulas, manufacturing processes, and technical and procedural manuals are kept confidential by the Company as agreed between the Company and the selling parties.
	Impairment of intangible assets —Intangible assets are evaluated at least annually for impairment if events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Based on the existence of one or more indicators of impairment, the Company measures any impairment of long-lived assets by comparing the asset's estimated fair value with its carrying value, based on cash flow methodology. Based on its review, the Company believes that, as of December 31, 2013 and 2012, there was no impairment of its intangible assets.
	Comprehensive income
	Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income is comprised of the foreign currency translation adjustments.
	Shipping and handling costs
	Shipping and handling costs related to costs of goods sold are included in selling expenses, which totaled $1,792,455 and $1,802,654 for the years ended December 31, 2013 and 2012, respectively.
Advertising costs
Advertising costs are charged to selling expenses as incurred. Advertising costs were insignificant for the years ended December 31, 2013 and 2012, respectively.
Research and development costs
Research and development costs are charged to expenses as incurred and include salaries, professional fees, and material costs and technical support fees related to such efforts.
Income taxes
The Company accounts for income taxes using an asset and liability method.  Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred income taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized.
A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. As of December 31, 2013 and 2012, there are no unrecognized tax benefits, and the Company does not expect a significant change in tax benefits in the next 12 months.  Penalties and interest levied by taxing authorities, if any, are classified as income tax expense in the year incurred. No significant penalties or interest relating to income taxes have been incurred during the years ended December 31, 2013 and 2012.
According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational or other errors made by the taxpayer or the withholding agent.  The statute of limitations extends to five years under special circumstances. In the case of transfer pricing issues, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. Accordingly, the income tax returns of the Company’s PRC operating subsidiaries for the years ended December 31, 2008 through 2013 are open to examination by the PRC state and local tax authorities.
Stock-based compensation
The Company records and reports stock-based compensation by measuring the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which services are received. Stock compensation for stock granted to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.
Earnings per share
Basic earnings per share is based upon the weighted-average number of common shares outstanding. Diluted earnings per share is based on the assumption that all dilutive convertible shares, including convertible preferred shares, warrants and stock options were converted or exercised. Further, the method requires that stock dividends or stock splits be accounted for retroactively if the stock dividends or stock splits occur during the period or after the end of the period but before the release of the financial statements, by considering it outstanding for the entirety of each period presented. Diluted earnings per share is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.
Related parties
Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of such principal owners and management, and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Operating segments
While the chief operating decision-makers monitor the revenue streams of the various products lines, operations are managed and financial performance is evaluated on a Company-wide basis. Product lines are aggregated into one as operating results for all product lines are similar. Accordingly, all of the major product lines (micro-organism, veterinary medicine, feed additives and vaccines) are considered by management to be aggregated in one reportable operating segment.
As the Company primarily generates its revenues from customers in the PRC, no geographical segments are presented.
Reclassifications
Certain amounts included in the 2012 financial statements have been reclassified to conform to the 2013 financial statement presentation as follows:
The Company has separately presented interest income of $97,591 on the face of consolidated statements of comprehensive income for the year ended December 31, 2012, instead of presented as part of other income, net of $39,933 and interest expenses, net of $57,658.
As a result of such reclassification, other income, net for the year ended December 31, 2012 has changed from $498,614 to $458,681 and interest expense, net has changed from $706,842 to $764,500.
The change in deferred government grant of $190,380 and due to related parties of $743,755 were classified into cash flows from financing activities in the Company’s consolidated statement of cash flows for the year ended December 31, 2012. The Company has reclassified these amounts as components of cash flows to operating activities.
As a result of such reclassification, net cash used in financing activities for the year ended December 31, 2012 has changed from $779,285 to $1,713,420, and net cash provided by operating activities has changed from $5,612,124 to $6,546,259.
Recently issued accounting pronouncements
In February 2013, the FASB issued Accounting Standards Update No. 2013-02 Comprehensive Income (Topic 220): The objective of this update is to improve the reporting of reclassifications out of accumulated other comprehensive income. The amendments in this update seek to attain that objective by requiring an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under U.S. generally accepted accounting principles (GAAP) to be reclassified in its entirety to net income. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under U.S. GAAP that provide additional detail about those amounts. This would be the case when a portion of the amount reclassified out of accumulated other comprehensive income is reclassified to a balance sheet account (for example, inventory) instead of directly to income or expense in the same reporting period. For public entities, the amendments are effective prospectively for reporting periods beginning after December 15, 2012. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.
In March 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2013-05, Foreign Currency Matters, (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (ASU 2013-05), to resolve a diversity in accounting for the cumulative translation adjustment of foreign currency upon derecognition of a foreign subsidiary or group of assets. ASU 2013-05 requires the parent to apply the guidance in Subtopic 830-30 to release any related cumulative translation adjustment into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. Further, ASU 2013-05 clarified that the parent should apply the guidance in subtopic 810-10 if there is a sale of an investment in a foreign entity, including both (1) events that result in the loss of a controlling financial interest in a foreign entity and (2) events that result in an acquirer obtaining control of an acquiree in which it held an equity interest immediately before the acquisition date. Accordingly, the cumulative translation adjustment should be released into net income upon the occurrence of those events. ASU 2013-05 is effective prospectively for the Company in our first quarter of fiscal 2014, with early adoption permitted. The Company does not expect ASU 2013-05 to have a significant impact on its consolidated results of operations and financial condition.
In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Income Taxes (Topic 740)(ASU 2013-11). The amendments in this update provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. These amendments provide that an unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except to the extent that a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date to settle any additional income taxes that would result from disallowance of a tax position, or the tax law does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, then the unrecognized tax benefit should be presented as a liability. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company does not expect ASU 2013-11 to have a significant impact on its consolidated results of operations and financial condition.
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

CONCENTRATIONS_AND_CREDIT_RISK

CONCENTRATIONS AND CREDIT RISK	12 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	Note 3 - CONCENTRATIONS AND CREDIT RISK
	The Company’s operations are all carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic, and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.
	Financial instruments which subject the Company to concentration of credit risk consist of cash and accounts receivable, prepayments to suppliers and others. Balances at financial institutions or state-owned banks within the PRC are not covered by insurance. The Company has not experienced any losses in such accounts. The Company provides unsecured credit terms for sales to customers and places unsecured prepayments for purchase to suppliers. As a result, there are credit risks with the accounts receivable and prepayment to suppliers balance.
	For the years ended December 31, 2013 and 2012, all of the Company’s sales occurred in the PRC. No major customers accounted for more than 10% of the Company’s total revenues in 2013 and 2012. All accounts receivable at December 31, 2013 and 2012 are from customers located in the PRC.
	The Company’s six largest vendors accounted for approximately 89% and 82% of the Company’s total purchases for the years ended December 31, 2013 and 2012, respectively. No other vendors accounted for more than 10% of the Company’s total purchases. As of December 31, 2013 and 2012, prepayments of $32,094,767 and $20,092,101 were made to the six largest vendors, respectively, for raw materials and packing materials purchases.
	The Company had one product that accounted for 13% and 15% of the Company’s total revenues for the years ended December 31, 2013 and 2012, respectively. No other products accounted for more than 10% of the Company’s total sales.

ACCOUNTS_RECEIVABLE_NET

ACCOUNTS RECEIVABLE, NET	12 Months Ended
	Dec. 31, 2013
Accounts Receivable Disclosure [Abstract]	'
Accounts Receivable Disclosure [Text Block]	'
	Note 4 - ACCOUNTS RECEIVABLE, NET
	Accounts receivable consisted of the following:
		December 31,		December 31,
		2013		2012
	Accounts receivable	$	11,611,741	$	10,258,065
	Allowance for doubtful accounts		-602,243		-247,269
	Accounts receivable, net	$	11,009,498	$	10,010,796
	The following table presents the movement of the allowance for doubtful accounts:
		December 31,		December 31,
		2013		2012
	Beginning of year	$	247,269	$	438,678
	Addition		1,335,664		166,276
	Reversal		-993,041		-361,247
	Translation adjustment		12,351		3,562
	End of year	$	602,243	$	247,269

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 5 – INVENTORIES
	Inventories consist of the following:
		December 31,		December 31,
		2013		2012
	Raw materials	$	23,001,461	$	20,428,757
	Packaging materials		396,067		220,078
	Work-in-process		23,140		219
	Finished goods		2,409,083		2,243,226
	Other		73,835		69,929
	Total	$	25,903,586	$	22,962,209
	During the year ended December 31, 2013 and 2012, the Company recorded a write-down of inventories of $nil and $16,026, respectively, which were predominately the result of expired raw material and outdated packing material.

DEPOSITS_PREPAID_EXPENSES_AND_

DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES	12 Months Ended
	Dec. 31, 2013
Deposits and Prepaid Expenses Disclosure [Abstract]	'
Deposits and Prepaid Expenses Disclosure [Text Block]	'
	Note 6 – DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES
	Deposits, prepaid expenses and other receivables are comprised of the following:
		December 31,		December 31,
		2013		2012
	Prepaid income taxes	$	-	$	1,263,845
	Other prepayments		478,144		828,676
	Deposits placed with guarantors (note 13)		491,100		198,375
	Interest receivable (note 7)		497,844		-
	Other receivables		667,075		548,954
	Total	$	2,134,163	$	2,839,850

PREPAYMENTS_TO_SUPPLIERS

PREPAYMENTS TO SUPPLIERS	12 Months Ended
	Dec. 31, 2013
Prepayments For Raw Materials Purchasing [Abstract]	'
Prepayments For Raw Materials Purchasing [Text Block]	'
	Note 7 – PREPAYMENTS TO SUPPLIERS
	Prepayments to suppliers are comprised of the following:
		December 31,		December 31,
		2013		2012
	Prepayments for raw materials	$	39,937,944	$	23,053,753
	Prepayments for packaging materials		1,123,200		384,982
	Total	$	41,061,144	$	23,438,735
	As part of the Company’s strategy to reduce inventory costs, the Company maintains a balance for prepayments to suppliers in order to secure favorable pricing for raw materials.  As inventory is received throughout the year, this balance will fluctuate with the business operations.
	Starting from January 1, 2013, the Company began to charge two major suppliers interest at an annual rate of 2.0% on these prepayments for raw materials. As of December 31, 2013, prepayments to these two suppliers were $31,953,084. For the years ended December 31, 2013 and 2012, $491,305 and $Nil, respectively, of interest income was recognized on these prepayments. The unpaid interest balance of $497,844 as of December 31, 2013 was included in “Deposits, prepaid expenses and other receivables” (note 6). The balance was fully settled in March 2014.

PROPERTY_PLANT_AND_EQUIPMENT_N

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment, Net [Text Block]	'
	Note 8 – PROPERTY, PLANT AND EQUIPMENT, NET
	Property, plant and equipment consist of the following:
		December 31,		December 31,
		2013		2012
	Buildings and improvements	$	27,703,872	$	27,210,008
	Machinery and equipment		6,093,533		5,876,467
	Office equipment and furniture		337,688		332,653
	Vehicles		611,989		593,296
	Total		34,747,082		34,012,424
	Less: accumulated depreciation		-6,477,927		-5,144,608
	Property, plant and equipment, net	$	28,269,155	$	28,867,816
	Depreciation expense was $1,467,261 and $1,035,829 for the years ended December 31, 2013 and 2012, respectively.
	As of December 31, 2013 and 2012, property, plant and equipment with a carrying amount of $19,969,335 and $2,180,382, respectively, were pledged against the Company’s short-term and long-term loans.

CONSTRUCTIONINPROGRESS

CONSTRUCTION-IN-PROGRESS	12 Months Ended
	Dec. 31, 2013
Construction In Progress Disclosure [Abstract]	'
Construction In Progress Disclosure [Text Block]	'
	Note 9 - CONSTRUCTION-IN-PROGRESS
	Construction-in-progress (“CIP”) relates to facilities being built in Xi’an, Jingzhou and Kunshan.
	Xi’an facility
	Xi’an Tianxing has a vaccine facility and animal laboratory being built in Huxian, Xi’an.
	In 2011, the Company started two projects at the vaccine facility to modify air filtration, water treatment, and other facility changes based on recommendations by outside experts hired by the Company to advise on the Good Morning Practices (“GMP”) qualification process for the vaccine facility. In September 2012, the China’s Ministry of Agriculture (“MOA”) physically inspected this facility and deemed the facility GMP compliant. Following physical inspection, the MOA’s inspection team recommended that the Office of the Working Committee proceed with Stage 2 of its GMP certification process.  On December 26, 2013, the MOA granted the GMP certificate for this new facility which is valid for five years. The facility is currently in the process of applying for individual product permits from the government. The Company expects to complete the application and launch the production in the second half of 2014. As of December 31, 2013, this vaccine facility had a total construction-in-progress of $2,484,212.
	In 2011, the Company started a facility improvement project in the amount of approximately $327,400 for the Huxian Animal Laboratory. The facility is a supporting project to the Huxian vaccine facility. The project was completed and passed GMP inspection in December 2013. The Company expects this facility to become operational once the Huxian vaccine facility launches its manufacturing in the second half of 2014.
	Jingzhou facility
	In 2011, the Company started a facility improvement project to expand the veterinary medicine production capacity at the Jingzhou facility. The project includes plant construction and water supply and drainage and has an estimated total cost of $1,718,850, of which $1,213,508 had been incurred as of December 31, 2013. Due to the revision in the project blueprint to comply with GMP requirements, the project was temporarily halted. The Company expects the project will be resumed in the second quarter of 2014 and be completed by the end of the fourth quarter of 2014.
	Kunshan facility
	In 2011, the Company started a supporting project at the Kunshan micro-organism facility that includes the construction and installation of plumbing, sewer, electrical, HVAC, fire protection and alarm system, drainage, office, lab, road construction, parking, and landscaping. As of December 31, 2013, the construction and installation of these facilities were completed, inspected and accepted. However, the construction-in-progress of $5,259,827 has not been transferred to property, plant and equipment as the Kunshan micro-organism facility was not operational at this point. During the third quarter of 2013, the Company contracted with an unrelated third party to purchase machinery and equipment at a total consideration of approximately $7,366,500, of which $3,513,002 was paid and was included in “Long-term prepayments” (note 11) as of December 31, 2013. The Company expects the purchase and installation of this equipment will be completed by the end of the third quarter of 2014.
	No depreciation is provided for construction-in-progress until such time as the assets are completed and placed into service.
	The construction projects the Company was in the progress of completing are as follows:
		Total in CIP
		as of
	Project	December 31,		Estimated Cost to		Estimated		Estimated
		2013		Complete		Total Cost		Completion Date
	Xi'an vaccine facility	$	2,484,212	$	-	$	2,484,212	Completed, Operational – Third quarter of 2014
	Xi'an animal laboratory		327,400		-		327,400	Completed, Operational – Third quarter of 2014
	Jingzhou veterinary medication facility		1,213,508		505,342		1,718,850	Fourth quarter of 2014
	Kunshan micro-organism facility		5,259,827		7,366,500		12,626,327	Construction - completed, Installation of machinery and
								equipment – Third quarter of 2014
	Total	$	9,284,947	$	7,871,842	$	17,156,789
	As of December 31, 2013 and 2012, the Company had construction in progress amounting to $9,284,947 and $8,691,360, respectively. Interest expense of $137,950 and $nil has been capitalized for construction in progress for the years ended December 31, 2013 and 2012, respectively.

LOANS_RECEIVABLE

LOANS RECEIVABLE	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Loans Receivable Disclosure [Text Block]	'
	Note 10 – LOANS RECEIVABLE
	In November 2010, the Company provided an unsecured non-interest bearing loan to Xi’an Tiantai Investment, Ltd., the Company’s acquisition advisor, in the amount of $190,400 (RMB 1,200,000) for two years from November 26, 2010 through November 25, 2012. On January 1, 2012, the Company changed this loan to an unsecured interest bearing loan at an annual interest rate of 12.0 % for eighteen months from January 1, 2012 to September 30, 2013. On June 28, 2013, the Company extended this loan for another six months from July 1, 2013 to December 31, 2013. On August 13, 2013, the entire loan was repaid.
	On April 1, 2012, the Company provided a secured interest bearing loan to Shaanxi Jiali Pharmaceutical Co., Ltd., an unrelated third party, in the amount of $793,500 (RMB 5,000,000) at an annual interest rate of 12.0 % for eight months from April 1, 2012 through November 30, 2012. This loan receivable was secured by an irrecoverable corporate guarantee from Xi’an Lantech Pharmaceutical Co. Ltd., an unrelated third party. On December 1, 2012, the Company extended this loan for another five months from December 1, 2012 to April 30, 2013. On May 8, 2013, the entire loan was repaid.
	As of December 31, 2013 and 2012, the Company had other unsecured non-interest bearing loans in the amount of $Nil and $94,887 respectively, due from the Company’s employees and unrelated third parties.
	Interest income earned on these loans amounted to $45,880 and $97,238 for the years ended December 31, 2013 and 2012, respectively.

LONGTERM_PREPAYMENTS

LONG-TERM PREPAYMENTS	12 Months Ended
	Dec. 31, 2013
Long Term Prepayments Disclosure [Abstract]	'
Long Term Prepayments Disclosure [Text Block]	'
	Note 11 - LONG-TERM PREPAYMENTS
	Long-term prepayments consist of the following:
		December 31,		December 31,
		2013		2012
	Deposits for equipment purchase and land use rights	$	3,871,228	$	311,227
	Prepayments for R&D projects		366,688		355,488
	Construction deposits		389,556		377,657
	Deposits for other		6,142		5,955
	Long-term prepayments - total	$	4,633,614	$	1,050,327
	Long-term prepayments for acquisitions	$	183,344	$	177,744
	As of December 31, 2013 and 2012, deposits for potential acquisitions totaled $183,344 and $177,744, respectively, all of which was held by an unrelated third party engaged to facilitate potential acquisition projects. On March 24, 2014, this deposit was fully refunded.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 12 – INTANGIBLE ASSETS
	Intangible assets consist of the following
		December 31,		December 31,
		2013		2012
	Land use rights	$	4,951,927	$	4,800,677
	Technological know-how		2,291,800		2,221,800
	Patents		327,400		317,400
	Total		7,571,127		7,339,877
	Less: accumulated amortization		-2,333,872		-2,020,046
	Intangible assets, net	$	5,237,255	$	5,319,831
	For the years ended December 31, 2013 and 2012, the amortization expense for intangibles assets amounted to $246,896 and $401,114, respectively.
	Amortization expense expected for the next five years and thereafter is as follows:
	Years ending December 31,	Amount
	2014	$	250,182
	2015		250,182
	2016		250,182
	2017		250,182
	2018		250,182
	Thereafter		3,986,345
	Total	$	5,237,255
	As of December 31, 2013 and 2012, land use rights with a carrying amount of $1,529,960 and $1,199,456, respectively, were pledged against the Company’s short-term loans.

SHORTTERM_AND_LONGTERM_LOANS

SHORT-TERM AND LONG-TERM LOANS	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Short-term Debt [Text Block]	'
	Note 13 – SHORT-TERM AND LONG-TERM LOANS
	Short-term loan
	On June 27, 2012, the Company entered into a line of credit agreement with Industrial and Commercial Bank of China (ICBC) Songzi Branch that allows the Company to borrow up to RMB 3,000,000. This line of credit agreement expired on June 18, 2013. The Company withdrew $476,100 (RMB 3,000,000) on July 3, 2012 at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate. This loan was secured by the Company’s buildings and land use rights in Jingzhou, Hubei Province. On June 18, 2013, the loan was fully repaid.
	On August 13, 2012, the Company obtained fifteen six-month loans with Xi'an High-tech Zone Guoxin Microcredit Ltd. for a total amount of RMB 15,000,000 to meet short-term cash needs. Each loan was in the amount of $158,700 (RMB 1,000,000) at an annual interest rate of 22.4 %. These loans were guaranteed by Sida. On February 5, 2013, the loans were fully repaid.
	On August 27, 2012, the Company obtained a one year loan with Chang’an Bank for RMB 10,000,000 at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate. This loan was guaranteed by Xi’an Taixin Investment Guarantee Co., Ltd. For this guarantee, the Company was required to pay RMB 200,000 of fees to Xi’an Taixin Investment Guarantee Co., Ltd. and 12.5% of the loan or $198,375 (RMB 1,250,000) is required to be kept by Xi’an Taixin Investment Guarantee Co., Ltd. to serve as collateral until the loan is repaid. This loan is also personally guaranteed by the Company’s Chairman and CEO. On August 28, 2013, the loan was fully repaid.
	On January 16, 2013, the Company obtained a one year loan with Industrial Bank Co. Ltd. Xi’an branch for $4,911,000 (RMB 30,000,000) at an annual interest rate of 6.6%. This loan is secured by the Company’s land use rights and manufacturing plant located in Huxian County. This loan is also personally guaranteed by the Company’s Chairman and CEO and his wife. On January 15, 2014, the loan was fully repaid.
	On April 16, 2013, the Company obtained a one year loan from May 27, 2013 to May 26, 2014 with Postal Savings Bank of China Xi’an Branch for $3,274,000 (RMB 20,000,000) at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 20% of that rate, which was 7.2% at December 31, 2013. This loan is guaranteed by Xi’an Investment and Financing Guarantee Co., Ltd. For this guarantee, the Company is required to pay $58,158 (RMB 360,000) of fees to Xi’an Investment and Financing Guarantee Co., Ltd. and 10% of the loan or $327,400 (RMB 2,000,000) is required to be kept by Xi’an Investment and Financing Guarantee Co., Ltd. to serve as collateral until the loan is repaid. This loan is secured by the Company’s office buildings located in Xi’an, Shaanxi Province and the manufacturing equipment in Huxian County. The Company’s Chairman and CEO, his wife, and two other company’s managers have provided personal guarantees to Xi’an Investment and Financing Guarantee Co., Ltd. for the repayment of the loan.
	On June 13, 2013, the Company obtained a one year loan from June 20, 2013 to June 19, 2014 with Industrial and Commercial Bank of China (ICBC) Songzi Branch for $818,500 (RMB 5,000,000) at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate, which was 7.8% at December 31, 2013. The Company is originally required to keep 10% of the loan or $81,850 (RMB 500,000) with the bank as collateral. During the fourth quarter of 2013, the collateral was waived. This loan is secured by the Company’s buildings and land use rights in Jingzhou, Hubei Province.
	On September 10, 2013, the Company entered into a loan agreement with its Chairman and CEO. Under the agreement, the Chairman and CEO obtained a one year personal bank loan from September 12, 2013 to September 11, 2014 with Bank of Beijing of $1,637,000 (RMB 10,000,000) and lent the entire loan proceeds to the Company. The interest and repayment terms of the loan from the Chairman and CEO are identical to those of the personal bank loan. The annual interest rate is determined by using the prime rate over the same period plus 30% of that rate, which was 7.8% at the date that the loan was issued. The Company agrees to bear all the costs and expenses associated with the personal bank loan. The personal bank loan is guaranteed by Xi’an Investment and Financing Guarantee Co., Ltd. For this guarantee, the CEO is required to (i) pay $29,079 (RMB 180,000) of fees to Xi’an Investment and Financing Guarantee Co., Ltd. This cost has been paid and recorded as an expense of the Company using the effective interest method for the year ended December 31, 2013; and (ii) place 10% of the loan or $163,700 (RMB 1,000,000) at Xi’an Investment and Financing Guarantee Co., Ltd. to serve as collateral until the loan is repaid. The Company had placed such a deposit with Xi’an Investment and Financing Guarantee Co., Ltd. as of December 31, 2013. The personal bank loan is also secured by the Chairman and CEO’s real estate properties and the Company’s office buildings and machineries located in Xi’an.
	Outstanding short-term loans consisted of the following:
			December 31, 2013					December 31, 2012							Interest
	Bank		Amt RMB		Amt USD			Amt RMB		Amt USD			Due Date		Rate
	ICBC Songzi Branch		-		$	-		3,000,000		$	476,100		6/18/13		-1
	Xi'an High-tech Zone Guoxin Microcredit Ltd.		-			-		15,000,000			2,380,500		2/12/13		22.4	%
	Chang’an Bank		-			-		10,000,000			1,587,000		8/26/13		-1
	Industrial Bank Co. Ltd. Xi’an Branch		30,000,000			4,911,000		-			-		1/15/14		6.6	%
	Postal Savings Bank of China Xi’an Branch		20,000,000			3,274,000		-			-		5/26/14		-2
	ICBC Songzi Branch		5,000,000			818,500		-			-		6/19/14		-1
	Related-party Individual – Chairman and CEO		10,000,000			1,637,000		-			-		9/11/14		7.8	%
	Total		65,000,000		$	10,640,500		28,000,000		$	4,443,600
		-1	People's Bank of China floating benchmark lending rate over the same period plus 30%, which was 7.8% at December 31, 2013.
		-2	People's Bank of China floating benchmark lending rate over the same period plus 20%, which was 7.2% at December 31, 2013.
	Long-term loan
	On September 17, 2012, the Company entered into a two-year line of credit agreement with Shaanxi Agricultural Yanta Credit Union that allows the Company to borrow up to RMB 8,000,000. This line of credit agreement expires September 20, 2014. The Company withdrew RMB 8,000,000 on September 26, 2012 at an annual interest rate of 9.446%. The interest rate was determined annually by using the People's Bank of China floating benchmark lending rate over the same period plus the lender’s floating rate. This line of credit was secured by the Company’s office buildings located in Xi’an City. This line of credit was also personally guaranteed by the Company’s Chairman and CEO and his wife. On May 9, 2013, the loans were fully repaid.
	Outstanding long-term loan consisted of the following:
			December 31, 2013						December 31, 2012							Interest
	Bank		Amt RMB			Amt USD			Amt RMB		Amt USD			Due Date		Rate
	Shaanxi Agricultural Yanta Credit Union			-			-		8,000,000		$	1,269,600		9/20/14			9.446	%
	Total			-		$	-		8,000,000		$	1,269,600
	Interest expense incurred and associated with the short-term and long-term loans amounted to $644,489 and $647,249 for the years ended December 31, 2013 and 2012, respectively, $137,950 and $nil has been capitalized as part of construction-in-progress in 2013 and 2012, respectively.

DEFERRED_GOVERNMENT_GRANT

DEFERRED GOVERNMENT GRANT	12 Months Ended
	Dec. 31, 2013
Deferred Government Grant Disclosure [Abstract]	'
Deferred Government Grant Disclosure [Text Block]	'
	Note 14 - DEFERRED GOVERNMENT GRANT
	The subsidies for Good Manufacturing Practice projects were granted by Shaanxi provincial government and Xi’an municipal government which may require the subsidies to be repaid. As of December 31, 2013 and 2012, the subsidies were RMB 2,500,000, equivalent to $409,250 and $396,750, respectively.
	The subsidies granted by Xi’an City Science and Technology Bureau and Xi’an City High-Tech Industrial Development Zone are required to be used exclusively for the fish disease multi associated anti-idiotypic monoclonal antibody vaccine project during the development period from January 2012 through December 2014. As of December 31, 2013 and 2012, 70% of the subsidies or RMB 4,200,000, equivalent to $687,540 and $666,540, respectively had been received and $491,100 (RMB 3,000,000) and nil has been expensed on this project and were accounted for as an offset against deferred government grant as of December 31, 2013 and 2012, respectively.
	The interest subsidies granted by Xi’an municipal government were required to be used exclusively for the chicken coccidia vaccine project in the third quarter of 2013. As of December 31, 2013, the subsidies or RMB 1,200,000, equivalent to $196,440 had been received and nil has been expensed on this project.

CAPITAL_TRANSACTIONS

CAPITAL TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 15 - CAPITAL TRANSACTIONS
	Stock-based compensation
	On March 31, 2012, the Company entered into an agreement with a non-executive director to grant him an aggregate 28,000 shares of restricted common stock each year under the Company’s 2010 Stock Incentive Plan, vested in four equal quarterly installments of 7,000 shares. The closing price per share of the stock on the next business day of each of the grant date in 2012 and 2013 was $2.95 and $1.73 respectively. The Board of Directors approved his agreement with the Company on March 10, 2014. As of December 31, 2013 and 2012, 49,000 and nil shares, respectively, were to be issued to this non-executive director.
	On May 26, 2009, the Company agreed to issue 5,556 shares of common stock to a director at the beginning of each term of his directorship, which runs from May 26, 2013 to May 25, 2014. In accordance with the agreement between the Company and this director, this director must continue to serve as a member of the Board until his successor is duly elected and qualified in order to receive the shares. As of December 31, 2013 and 2012, 11,112 shares and 5,556 shares, respectively, were to be issued to this non-executive director.
	On July 29, 2011, the Company entered into a one-year employment agreement with its CFO effective July 29, 2011. Under the agreement, he is entitled to receive an aggregate 8,000 shares of common stock, 4,000 shares of which shall be issuable on the 6 month anniversary and the remaining 4,000 shares of which shall be issuable on the 12 month anniversary. The closing price per share on the grant date was $4.20. On July 29, 2012, the Company entered into another one-year employment agreement with the CFO effective July 29, 2012. Under the agreement, he is entitled to receive an aggregate 8,000 shares of common stock, vested in four equal quarterly installments of 2,000 shares. The closing price per share of the stock on the next business day of the grant date was $2.17. On July 29, 2013, the Company entered into another one-year employment agreement with the CFO effective July 29, 2013. Under the agreement, he is entitled to receive an aggregate 8,000 shares of common stock, vested in four equal quarterly installments of 2,000 shares. The closing price per share of the stock on the next business day of the grant date was $1.37.The Board of Directors ratified and approved the CFO’s employment agreement with the Company on March 10, 2014. As of December 31, 2013 and 2012, 10,000 shares and 2,000 shares were vested and to be issued to this executive, respectively.
	The Company entered into a five-year employment agreement with its Chief Executive Officer on May 5, 2008. After the agreement was expired on December 31, 2013, the Company renewed the employment agreement with its Chief Executive Officer for another five year period effective January 1, 2014. Under the agreement, he is entitled to receive an aggregate 50,000 shares of common stock each year, vested in four equal quarterly installments of 12,500 shares. The Board of Directors approved the CEO’s employment agreement with the Company on March 10, 2014.
	The Company recorded $143,549 and $86,162 share based compensation for the years ended December 31, 2013 and 2012. Shares to be issued to related parties included in other payables and accrued expenses of $29,342 as of December 31, 2012 were transferred to paid in capital during the year.
	Equity Compensation Plan
	On December 8, 2009, the Company’s board of directors approved a stock incentive plan for officers, directors, employees and consultants entitled the “Skystar Bio-Pharmaceutical Company 2010 Stock Incentive Plan” (the “2010 Plan”). The maximum number of shares that may be issued under the 2010 Plan is 700,000 shares of common stock. The 2010 Plan was approved by the Company’s stockholders on December 31, 2009, and awards may be granted thereunder until December 7, 2019. On May 4, 2012, the Board approved common stock grants in the total amount of 442,881 shares to the Company’s employees and members of the Board of Directors, all of which grants were made pursuant to the terms and provisions of the Plan. As of December 31, 2013 and 2012, there are 247,119 shares of the Company’s common stock remaining available for future issuance under the Plan. As of December 31, 2013 and 2012, there are 70,112 shares and 7,556 shares, respectively, vested pending to be issued.
	A summary of changes in the Company’s non-vested shares for the year follows:
			Non-vested Shares
	Non-vested at January 1, 2012			17,000
	Granted			13,556
	Vested			-24,556
	Forfeited			-
	Non-vested at December 31, 2012			6,000
	Granted			69,556
	Vested			-62,556
	Forfeited			-
	Non-vested at December 31, 2013			13,000
	As of December 31, 2013, there was $18,423 of total unrecognized compensation cost related to non-vested shares granted.  The total fair value of shares vested during the years ended December 31, 2013 and 2012 was $144,663 and $86,162, respectively, based on the closing price of the Company’s common stock on the grant date.
	Purchase Options
	In connection with the 2009 equity offering, the Company granted 140,000 common stock purchase options to five designees of the Underwriters with a vesting date of June 30, 2010. The options are exercisable from June 30, 2010 to June 30, 2014, and each option is exercisable for one share of the Company’s common stock at an exercise price at $8.11 per share. All options were provided for services performed. As of December 31, 2013 and 2012, 140,000 common stock purchase options remained outstanding.
	Outstanding purchase options do not trade in an active securities market, and as such, the Company estimates the fair value of these purchase options using the Black-Scholes Option Pricing Model (“Black-Scholes Model”) using the following assumptions:
			Purchase Options
			December 31,				December 31,
			2013				2012
	Stock price		$	3.51			$	1.6
	Exercise price		$	8.11			$	8.11
	Annual dividend yield			-				-
	Expected term (years)			0.5				1.5
	Risk-free interest rate			0.1	%			0.16	%
	Expected volatility			125	%			73	%
	Option value		$	0.45			$	0.04
		-1	As of December 31, 2013 and 2012, 140,000 purchase options with an exercise price of $8.11 were outstanding.
	Expected volatility is based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods that correspond to the term of the warrants. The Company believes this method produces an estimate that is representative of future volatility over the expected term of these warrants and purchase options. The Company has no reason to believe future volatility over the expected remaining life of these purchase options is likely to differ materially from historical volatility. The expected life is based on the remaining term of the purchase options. The risk-free interest rate is based on U.S. Treasury securities according to the remaining term of the purchase options.
	As required by the FASB’s accounting standards, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Depending on the nature and the terms of the transaction, the fair values of the warrant/purchase option liability were modeled using a series of techniques, including closed-form analytic formula, such as the Black-Scholes Model, which does not entail material subjectivity because the methodology employed does not necessitate significant judgment, and the pricing inputs are observed from actively quoted markets.
	The fair value of the 140,000 purchase options outstanding as of December 31, 2013 and 2012 was determined using the Black-Scholes Model, utilizing level 2 inputs, and the change was recorded in earnings. The Company recognized a loss of $56,840 and a gain of $37,800 from the change in fair value of derivative liability for the year ended December 31, 2013 and 2012, respectively.
	Following is an activity summary of the Company’s outstanding purchase options:
			Number of		Weighted –			Weighted-
			purchase		average			average
			options		exercise price			remaining
								contractual term
								(Year)
	Outstanding at January 1, 2011		174,230		$	7.5		2.04
	Granted		-
	Forfeited		-34,230			5
	Exercised		-
	Outstanding at December 31, 2012		140,000		$	8.11		1.5
	Granted		-
	Forfeited		-
	Exercised		-
	Outstanding at December 31, 2013		140,000		$	8.11		0.5
	Exercisable at December 31, 2013		140,000		$	8.11		0.5
	On February 28, 2007, the Company issued warrants to the placement agents, exercisable for 114,100 shares of the Company’s common stock at a price of $5.00 per share for a five-year term (number of warrants and exercise price adjusted for 1 for 10 reverse stock split on May 12, 2009 and 2 for 1 forward stock split on November 6, 2009. All the remaining 34,230 warrants expired on February 28, 2012.

STATUTORY_RESERVES

STATUTORY RESERVES	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 16 - STATUTORY RESERVES
	Statutory reserves represent restricted retained earnings. Based on the legal formation of the entities, all PRC entities are required to set aside 10% of net income as reported in their statutory accounts on an annual basis to the statutory surplus reserve fund. Once the total statutory surplus reserve reaches 50% of the entity’s registered capital, further appropriations are discretionary. The statutory surplus reserve can be used to increase the entity’s registered capital (upon approval by relevant government authorities) and eliminate its future losses under PRC regulatory requirements (upon a resolution by the board of directors). The statutory surplus reserve is not distributable to shareholders except in the event of liquidation.
	Appropriations to the above statutory reserves are accounted for as a transfer from unrestricted earnings to statutory reserves. There are no legal requirements in the PRC to fund these statutory reserves by the transfer of cash to any restricted accounts, and as such, the Company has not transferred any cash to these accounts. These reserves are not distributable as cash dividends.

TAXES

TAXES	12 Months Ended
	Dec. 31, 2013
Taxes Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 17 – TAXES
	Provision for income taxs consisted of the following:
	PRC income taxes		December 31,		December 31,
			2013		2012
	Current		$	2,760,936	$	2,168,125
	Deferred			-359,628		-
	Total		$	2,401,308	$	2,168,125
	Skystar is subject to United States federal income tax. Skystar Cayman is a tax-exempt company incorporated in the Cayman Islands. Fortune Time did not have any assessable profits arising in or derived from Hong Kong for the years ended December 31, 2013 and 2012, and accordingly no provision for Hong Kong profits tax was made in these years.
	The Company’s subsidiaries and VIEs are subject to the PRC’s Enterprise Income Tax. Pursuant to the PRC Income Tax Laws, Enterprise Income Tax is generally imposed at a statutory rate of 25%. Xi’an Tianxing has been approved as a new technology enterprise, and under PRC Income Tax Laws is entitled to a preferential tax rate of 15 %.
	The following table reconciles the U.S. statutory rates to the Company’s effective tax rate for the years ended December 31, 2013 and 2012:
			Years ended December 31,
			2013		2012
	U.S. Statutory rate		34	%	34	%
	Foreign income not recognized in the U.S.		-34		-34
	China income tax rate		25		25
	China income tax exemption		-10		-10
	Other item (1)		3.6		10.9
	Total provision for income taxes		18.6	%	25.9	%
		-1	Other items are primarily for operating expenses (income) incurred by Skystar that are not deductible (taxable) in the PRC, expenses incurred by other subsidiaries that are not deductible on the consolidated level, the difference of taxable income under US GAAP rather than Chinese GAAP, and the difference of Enterprise Income Tax imposed at a statutory rate of 25% rather than preferential tax rate of 15% on the income from the subsidiaries other than Xi’an Tianxing, which resulted in an increase in the effective tax rate of 3.6% and 10.9% for the years ended December 31, 2013 and 2012, respectively.   Other items consisted of the following:
		Years ended December 31,
		2013			2012
	Income taxed at Chinese statutory rate of 25%		0.2	%		4.4	%
	Valuation allowance on tax loss		1.5			1.8
	Non-deductible operating expenses		1.9			4.7
	Total other items		3.6	%		10.9	%
	Taxes payable consisted of the following:
			December 31,		December 31,
			2013		2012
	Income taxes		$	662,811	$	279,680
	Value added taxes			576,603		1,409,762
	Other taxes			76,072		261,315
	Total		$	1,315,486	$	1,950,757
	As of December 31, 2013 and 2012, the estimated net operating loss carry forwards of Skystar for U.S. income tax purposes amounted to $4,917,108 and $4,711,862, which may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized, beginning in 2025 and through 2033. As of December 31, 2013 and 2012, the estimated net operating loss carry forwards of Skystar for PRC income tax purposes amounted to $4,572,233 and $3,467,227, which may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized, through 2018. Management believes that the realization of the arising from this loss appears to be uncertain due to the Company’s limited operating history and continuing losses for U.S. and PRC income tax purposes. Accordingly, the Company has provided a 100% valuation allowance at December 31, 2013 and 2012. As of December 31, 2013 and 2012, the valuation allowance on the tax loss of Skystar was $1,671,817 and $1,602,033, respectively, and that of PRC subsidiaries was $1,142,813 and $866,807, respectively. The Company’s management reviews this valuation allowance periodically and makes adjustments as necessary. As of December 31, 2013, the Company had deferred tax assets amounting to $364,425 in respect of accrued expenses of $213,685 and an allowance on doubtful accounts of $150,560. As of December 31, 2012, the Company had no other deferred tax amounts.
	The Company did not provide for deferred income taxes and foreign withholding taxes on the cumulative undistributed earnings of foreign subsidiaries as of December 31, 2013 and 2012 of approximately $50.9 million and $35.6 million, respectively. The cumulative undistributed earnings of foreign subsidiaries were included in consolidated retained earnings and will continue to be indefinitely reinvested in international operations.  Accordingly, no provision has been made for U.S. deferred taxes or applicable withholding taxes, related to future repatriation of these earnings, nor is it practicable to estimate the amount of income taxes that would have to be provided if management concluded that such earnings will be remitted in the future.

EARNINGS_PER_SHARE

EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 18 - EARNINGS PER SHARE
	The earnings per share are as follows:
		Years ended December 31,
		2013		2012
	Net income	$	10,530,252	$	6,212,428
	Weighted average shares used in basic computation		7,651,640		7,471,350
	Effect of dilutive potential non-vested common shares		4,446		-
	Weighted average shares used in diluted computation		7,656,086		7,471,350
	Earnings per share:
	Basic	$	1.38	$	0.83
	Diluted	$	1.37	$	0.83
	For the years ended December 31, 2013, the outstanding 140,000 options were excluded from the diluted earnings per share calculation as they are anti-dilutive.
	For the years ended December 31, 2012, the outstanding 140,000 options and 6,000 non-vested shares were excluded from the diluted earnings per share calculation as they are anti-dilutive.

RELATED_PARTY_TRANSACTIONS_AND

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 19 - RELATED PARTY TRANSACTIONS AND ARRANGEMENTS
	Amounts receivable from and payable to related parties are summarized as follows:
			December 31,		December 31,
			2013		2012
	Amounts due to related parties
	Weibing Lu – CEO (1)		$	857,012	$	608,282
	Bing Mei – CFO (2)			41,283		264
	Scott Cramer – non-executive director and shareholder (2)			300,203		138,169
	Directors, shareholders and other related parties (3)			163,050		52,210
	Total		$	1,361,548	$	798,925
		-1	As of December 31, 2013 and 2012, the Company had unpaid reimbursement, compensation, and advances for business expenses due to Weibing Lu valued at $857,012 and $608,282, respectively.
		-2	As of December 31, 2013 and 2012, the Company had unpaid reimbursement and compensation due to Scott Cramer valued at $300,203 and $138,169, respectively. On March 10, 2014, the Board of Directors, including all of the independent members of the Board, reviewed and approved the terms of Mr. Cramer’s Consulting Services Agreement with the Company pursuant to which the Company would continue employing him as its US representative in consideration of (i) a quarterly cash fee of $7,500, (ii) 7,000 restricted shares of the Company’s common stock issuable on a quarterly basis pursuant to the Company’s 2010 Stock Incentive Plan, and (iii) reimbursement of out of pocket expenses.  In addition, Mr. Cramer agreed to pay certain invoices of the Company to its vendors (and the Company agreed to reimburse Mr. Cramer) in the form of a no interest bearing loan in the aggregate amount of approximately $250,000.  As of December 31, 2013 and 2012, the Company had unpaid reimbursement and compensation due to Bing Mei valued at $41,283 and $264, respectively.
		-3	The amounts due to directors, shareholders and other related parties at December 31, 2013 and 2012 include unpaid reimbursement and advances to other related parties for business expenses.
	Also refer to Notes 13, 15 and 20 for other related party transactions and arrangements.
	Exchange of leasehold interest:
	In 2005, a shareholder contributed a leasehold interest with a carrying amount of $363,414 (RMB 2,220,000) as additional capital of Xi’an Tianxing but the title of this leasehold property was not passed to the Company. In December 2013, this shareholder exchanged this leasehold interest in return for amounts due to the shareholder of $486,427 (RMB 3,010,000), which approximated the fair value on the date of the exchange. The difference in the carrying amount of the amounts due to the shareholder and the leasehold interest of $437,166 was credited to additional paid in capital.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 20 - COMMITMENTS AND CONTINGENCIES
	(a)  Lease commitments
	The Company recognizes lease expense on the straight-line basis over the term of the lease.
	The Company entered into a tenancy agreement for the lease of factory premises of Xi’an Tianxing in Sanqiao for a period of ten years from October 1, 2004 to December 31, 2014. The annual rent for the factory premises is subject to a 10% increase every two years starting October 1, 2009. As of December 31, 2013, the annual rent for the factory premises was approximately $22,977 (RMB 140,360).
	The Company leased office space in Xi’an from Mr. Weibing Lu, the Company’s Chairman and CEO, for a period of five years from January 1, 2007 to December 31, 2011. In January 2012, the Company renewed the lease with Mr. Lu for another 5 years from January 1, 2012 to December 31, 2016 at a rent of approximately $29,466 (RMB 180,000) per year.
	The Company also entered into a tenancy agreement with Mr. Weibing Lu for the lease of Shanghai Siqiang’s office in Shanghai for a period of ten years from August 1, 2007 to August 1, 2017 with an annual rent of approximately $23,573 (RMB 144,000).
	The Company entered into a one year tenancy agreement for an office lease in Kunshan, Jiangsu Province from April 15, 2011 to April 14, 2012 with an annual rent of approximately $3,143 (RMB 19,200). On April 15, 2012, the Company entered into a six-month tenancy agreement for this office from April 15, 2012 to October 14, 2012 with six-month rent of approximately $1,703 (RMB 10,405). On October 15, 2012, the Company entered into a another six-month tenancy agreement for this office from October 15, 2012 to April 14, 2013 with a six-month rent of approximately $1,703 (RMB 10,405). On April 15, 2013, the Company entered into a another one-year tenancy agreement for this office from April 15, 2013 to April 14, 2014 with a one-year rent of approximately $3,853 (RMB 23,536 ).
	The Company entered into a tenancy agreement for the lease of warehouse premises in Xi’an for a period of three years from July 20, 2011 to July 19, 2014 with an annual rent of approximately $38,469 (RMB 235,000) subject to a 10% increase every two years starting July 20, 2013. As of December 31, 2013, the annual rent for the warehouse premises was approximately $42,316 (RMB 258,500).
	The Company entered into a tenancy agreement for the lease of a sales office in Jingzhou, Hubei Province for a period of five years from April 18, 2012 to April 17, 2017 with an annual rent of approximately $8,840 (RMB 54,000) for the first three years subject to increase during last two years.
	The minimum future lease payments for the next five years and thereafter are as follows:
	Period	Unrelated third		Related parties		Total
		parties
	Year ending December 31, 2014	$	52,291	$	53,039	$	105,330
	Year ending December 31, 2015		8,840		53,039		61,879
	Year ending December 31, 2016		8,840		53,039		61,879
	Year ending December 31, 2017 and thereafter		2,210		13,751		15,961
	Total	$	72,181	$	172,868	$	245,049
	Rental expense to unrelated third parties for the years ended December 31, 2013 and 2012 amounted to $79,467 and $62,620, respectively. Rental expense to related parties for the years ended December 31, 2013 and 2012 amounted to $52,342 and $51,403, respectively.
	(b)  Legal proceedings
	From time to time, the Company is involved in legal matters arising in the ordinary course of business. Management currently is not aware of any legal matters or pending litigation that would have a significant effect on the Company’s consolidated financial statements as of December 31, 2013.
	In May 2007, Andrew Chien filed suit against the Company, R. Scott Cramer, Steve Lowe, David Wassung and Weibing Lu in United States District Court for the District of Connecticut, alleging causes of action for violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 17, 2008, in a decision that is now published, the court granted defendants’ motion to dismiss and subsequently dismissed the lawsuit, entering judgment on behalf of the defendants. Chien appealed the dismissal. Defendants filed a post judgment motion for sanctions against Chien. On February 5, 2009, the court found the action filed by Chien to have been frivolous, and to have constituted a “substantial” violation of Rule 11, and imposed monetary sanctions on both Chien and his former attorney. Chien appealed the award of sanctions. All appeals, including the one referenced below concerning Chien’s second lawsuit, were subsequently consolidated. The Court of Appeals issued a Mandate upholding the decision granting defendant’s motion to dismiss and found that the District Court did not “abuse its discretion” in issuing sanctions against Chien in light of the circumstances and facts on record. This Mandate was entered on or about November 8, 2010.
	Andrew Chien, proceeding pro se (i.e., he represented himself without an attorney), filed his second lawsuit against the Company, R. Scott Cramer, Steve Lowe, David Wassung and Weibing Lu in Connecticut Superior Court (which was removed to U.S. District Court) alleging causes of action similar to those alleged in his federal complaint described above as well as state law causes of action. The court held that all claims asserted against the defendants were barred and failed to state a claim on a multiplicity of grounds, including on the basis of res judicata. Defendants filed a second Motion for Sanctions under Rule 11 and the PSLRA, which was granted. Chien appealed the dismissal. The Court of Appeals for the Second Circuit consolidated all of Chien’s appeals from both of his lawsuits. On November 8, 2010, the Court of Appeals affirmed the dismissals and the awards of sanctions. On January 22, 2011, Chien filed a petition with the Supreme Court of the United States, appealing the lower court’s ruling. The Supreme Court denied review of the petition.
	Andrew Chien, again proceeding pro se, commenced his third lawsuit against the Company, Scott Cramer, Steve Lowe, David Wassung, Weibing Lu (and also Weinberg & Company, P.A., Moore Stephens Wirth Frazer & Torbet, LLP, Frazer Frost, LLP, Crowe Horwath LLP, Richardson & Patel LLP, Kevin K. Leung, Harvey Kesner, and Jody M. Borrelli) alleging the same facts and circumstances as set forth in the above two matters, although adding the aforementioned accountants and lawyers as defendants to the claims. The matter commenced on August 8, 2011, and shortly thereafter was removed to U.S. District Court. On October 5, 2011, the court dismissed the entire action as to all defendants. As in the two previous lawsuits, sanctions were issued against Chien. Moreover, the District Court issued an order prohibiting Chien from filing any more lawsuits against the defedentants without prior approval from the court. Chien appealed the Court’s ruling to the United States Court of Appeals for the Second Circuit, where all defendants have filed motions to dismiss.
	The United States Court of Appeals for the Second Circuit recently affirmed the judgments and orders of the United States District Court and dismissed all of Mr. Chien’s pending appeals.
	Although the Second Circuit declined to issue sanctions against Chien, it expressly warned Chien “that the continued filing of duplicative, vexatious, or frivolous appeals regarding issues already resolved by this Court may result in the imposition of sanctions, including a leave-to-file sanction requiring Chien to obtain permission from this Court prior to filing further submissions in this Court.” The Supreme Court of the United States denied Chien’s petition for writs of certiorari.
	(c) R&D project
	In 2008, Xi’an Tianxing contracted with Northwestern Agricultural Technology University to work jointly on an R&D project concerning the application of nano-technology in the prevention of major milk cow disease. The total projected budget for this project is approximately $654,800 (RMB 4,000,000), which is to be paid according to completed stages of the project. The project reached trial stage in September 2009. As of December 31, 2013, the Company incurred approximately $572,950 (RMB 3,500,000) of cumulative expenses relating to this project.
	In 2009, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project on fish diseases linked immunosorbent detection kit and fish diseases multi-linked monoclonal antibody therapeutic agents. The contracted amount for this project is approximated $982,200 (RMB 6,000,000). As of December 31, 2013, the Company has incurred approximately $851,240 (RMB 5,200,000) of cumulative expenses relating to this project.
	During the first quarter of 2011, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project to develop new treatment and diagnosis method for Mycoplasmal pneumonia of swine. The project term is from January 2011 through September 2013. The cost to the Company for the initial phase is approximately $327,400 (RMB 2,000,000). As of December 31, 2013, the project was extended for clinical trials and the Company has incurred approximately $245,550 (RMB 1,500,000). The project is expected to be completed by the end of 2015.
	During the second quarter of 2012, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project of ring disease and pseudo-rabies specific transfer factor and blue-ear disease and Mycoplasma pneumoniae disease specific transfer factor to enhance the livestock and poultry's own immuneforce and prevent the onset of conventional disease. The project term is from April 2012 through March 2013. As of December 31, 2013, the project was completed and the Company incurred expenses of $50,747 (RMB 310,000).
	During the fourth quarter of 2012, Xi’an Tianxing launched eight in-house R&D projects as set forth in the following table. As of December 31, 2013, the Company incurred all the budget expenses and these projects were still under development.
	During the second quarter of 2013, Xi’an Tianxing launched an R&D project to develop monoclonal antibody vaccine to prevent common fish skin disease. The cost to the Company for this project is approximately $572,950 (RMB 3,500,000). As of December 31, 2013, the Company has incurred $491,100 (RMB 3,000,000) and this project is still under development.
	During the third quarter of 2013, Xi’an Tianxing launched an R&D project to develop livestock and avian disease multi-joint yolk antibody therapeutic agents and contracted with Lantian County Chicken Farm to test the effect of its developed agents. The project is expected to be completed by the end of 2014. The total projected budget for this project is approximately $720,280 (RMB 4,400,000). As of December 31, 2013, the Company has incurred $327,400 (RMB 2,000,000) and this project is still under development.
	In addition, the Company also launched various R&D projects on veterinary products formula adjustment, pet drug development, fermentation engineering design and development, GMP inspection trial production tests and lab tests. As of December 31, 2013, $1,676,100 (RMB 10,238,854) has been incurred related to these projects and lab tests.
	R&D projects are summarized as follows:
	Project	Amount		Amount		Total amount
		incurred as		expected to be		of
		of 12/31/2013		incurred		project
	Project with Northwestern Agricultural Technology University
	Application of nano-technology in the prevention of major milk cow disease	$	572,950	$	81,850	$	654,800
	Project with the Fourth Military Medical University
	Fish diseases linked immunosorbent detection kit and fish diseases Multi-linked monoclonal antibody therapeutic agents		851,240		130,960		982,200
	New treatment and diagnosis method for Mycoplasmal pneumonia of swine		245,550		81,850		327,400
	Transfer factor test		50,747		-		50,747
	In-house R&D project during 2012
	Oral liquid products R&D and field trials		163,700		-		163,700
	Powder for injection products R&D and field trials		163,700		-		163,700
	Vitamin E injection product development		81,850		-		81,850
	Anthelmintic product development		81,850		-		81,850
	Three disease grams product development		81,850		-		81,850
	Premixes class product development		81,850		-		81,850
	Bulk powder products development		81,850		-		81,850
	Livestock and fish diseases immunoassay kit development		409,250		-		409,250
	In-house R&D project during 2013
	Fish monoclonal antibody vaccine		491,100		81,850		572,950
	Livestock and avian disease multi-joint yolk antibody therapeutic agents		327,400		392,880		720,280
	Other projects for veterinary products formula adjustment, pet drug development, fermentation engineering design and development, GMP inspection trial production tests and other lab tests		1,676,100		16,370		1,692,470
	Total	$	5,360,987	$	785,760	$	6,146,747
	All payments made for R&D projects have been expensed as incurred.
	(d) Registered capital commitment:
	Skystar Kunshan’s remaining registered capital of $12,750,000 was originally required to be invested by May 7, 2012. On March 26, 2014, the Company received the approval of extension for payment of the remaining registered capital by May 6, 2015.
	(e) Capital commitment
	The Company’s commitments for capital expenditure as of December 31, 2013 are as follows:
Contracted but not accrued for:
Purchase of machinery and construction (Note 9)	$	4,358,840

SEGEMENT_INFORMATION

SEGEMENT INFORMATION	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 21 – SEGEMENT INFORMATION
	The Company currently engages in one business segment, the research, development, production, marketing and sales of veterinary healthcare and medical care products. The Company’s revenues and cost of revenues by product line were as follows:
		Years Ended December 31,
		2013		2012
	Revenues
	Veterinary Medications	$	25,515,844	$	10,658,359
	Micro-organism		13,546,118		15,355,467
	Feed Additives		1,790,981		4,021,567
	Vaccines		1,630,773		3,551,398
	Total Revenues	$	42,483,716	$	33,586,791
	Cost of Revenues
	Veterinary Medications	$	15,181,929	$	6,087,300
	Micro-organism		4,119,721		5,498,463
	Feed Additives		1,365,794		3,074,301
	Vaccines		325,518		434,940
	Total Cost of Revenues		20,992,962		15,095,004
	Gross Profit	$	21,490,754	$	18,491,787

RESTRICTED_NET_ASSETS

RESTRICTED NET ASSETS	12 Months Ended
	Dec. 31, 2013
Restricted Cash and Investments, Current [Abstract]	'
Restricted Assets Disclosure [Text Block]	'
	Note 22 - RESTRICTED NET ASSETS
	Schedule I of Article 5-04 of Regulation S-X requires the condensed financial information of registrant (Parent Company) shall be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. For purposes of this test, restricted net assets of consolidated subsidiaries shall mean that amount of the registrant’s proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of a third party (i.e., lender, regulatory agency, foreign government, etc.).
	The condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X as the restricted net assets of the subsidiaries of Skystar Bio-Pharmaceutical Company exceed 25% of the consolidated net assets of Skystar Bio-Pharmaceutical Company. The ability of our Chinese operating affiliates to pay dividends may be restricted due to the foreign exchange control policies and availability of cash balances of the Chinese operating subsidiaries. Because a significant portion of our operations and revenues are conducted and generated in China, all of our revenues being earned and currency received are denominated in Renminbi (RMB). RMB is subject to the exchange control regulation in China, and, as a result, we may be unable to distribute any dividends outside of China due to PRC exchange control regulations that restrict our ability to convert RMB into US Dollars.

SCHEDULE_I_CONDENSED_FINANCIAL

SCHEDULE I CONDENSED FINANCIAL INFORMATION OF REGISTRANT	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Condensed Financial Information of Parent Company Only Disclosure [Text Block]	'
	SCHEDULE I – CONDENSED FINANCIAL INFORMATION OF REGISTRANT
	PARENT COMPANY STATEMENTS OF OPERATIONS
		Years ended December 31,
		2013		2012
	REVENUE, net	$	-	$	-
	OPERATING EXPENSES:
	Salaries and consulting expenses		384,513		272,660
	General and administrative		836,098		1,819,709
	Total operating expenses		1,220,611		2,092,369
	LOSS FROM OPERATIONS		-1,220,611		-2,092,369
	OTHER INCOME (EXPENSE):
	Change in fair value of purchase option liability		-56,840		37,800
	Other income		-		13,819
	Total other income (expense), net		-56,840		51,619
	(LOSS) ATTRIBUTABLE TO PARENT COMPANY		-1,277,451		-2,040,750
	EQUITY IN EARNINGS OF SUBSIDIARIES		11,807,703		8,253,178
	NET INCOME AVAILABLE TO SHAREHOLDERS	$	10,530,252	$	6,212,428
	PARENT COMPANY BALANCE SHEETS
		December 31,		December 31,
		2013		2012
	ASSETS
	CURRENT ASSETS:
	Cash	$	920	$	968
	Prepaid expenses and other current assets		258,370		283,836
	Total current assets		259,290		284,804
	Interests in subsidiaries		111,331,905		96,750,650
	Total assets	$	111,591,195	$	97,035,454
	LIABILITIES AND SHAREHOLDERS' EQUITY
	CURRENT LIABILITIES:
	Accounts payable and accrued expenses	$	120,720	$	126,062
	Salary and consulting fees payable		71,972		71,838
	Due to related parties		943,087		617,021
	Total current liabilities		1,135,779		814,921
	OTHER LIABILITIES:
	Purchase option liability		62,440		5,600
	Total liabilities		1,198,219		820,521
	SHAREHOLDERS' EQUITY		110,392,976		96,214,933
	Total liabilities and shareholders' equity	$	111,591,195	$	97,035,454
	PARENT COMPANY STATEMENTS OF CASH FLOWS
		Years ended December 31,
		2013		2012
	CASH FLOWS FROM OPERATING ACTIVITIES:
	Net income available to shareholders	$	10,530,252	$	6,212,428
	Adjustments to reconcile net income to net cash used in operating activities:
	Equity in earnings of subsidiaries		-11,807,703		-8,253,178
	Common stock to be issued to related parties for compensation		143,549		86,162
	Common stock issued under 2010 stock incentive plan		-		1,037,911
	Change in fair value of purchase option liability		56,840		-37,800
	Change in operating assets and liabilities
	Prepaid expenses and other current assets		25,466		-27,836
	Accounts payable and accrued expenses		-5,342		-401,077
	Salary and consulting fees payable		134		-273,050
	Increase in due to related parties		565,496		326,630
	Net cash used in operating activities		-491,308		-1,329,810
	CASH FLOWS FROM INVESTING ACTIVITIES:
	Decrease in interest in subsidiaries		491,260		1,318,270
	Net cash provided by investing activities		491,260		1,318,270
	CASH FLOWS FROM FINANCING ACTIVITIES:
	Net cash provided by financing activities		-		-
	DECREASE IN CASH		-48		-11,540
	CASH, beginning of year		968		12,508
	CASH, end of year	$	920	$	968
	The condensed parent company financial statements have been prepared using the equity method to account for its subsidiaries. Refer to the consolidated financial statements and notes presented above for additional information and disclosures with respect to these financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of consolidation
	The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries, and its variable interest entities (“VIEs”).  All significant inter-company transactions and balances between the Company, its subsidiaries, and its VIEs have been eliminated in consolidation.
	The Company has evaluated the relationship with Xi’an Tianxing and Xi’an Tianxing’s wholly owned subsidiaries, Xi’an Sikaida and Shanghai Siqiang. As a result of the contractual arrangements which obligate Sida to absorb all of the risk of loss from Xi’an Tianxing’s activities and enable Sida to receive all of its expected residual returns, the Company is the primary beneficiary of these VIEs and thus it accounts for Xi’an Tianxing, Xi’an Sikaida and Shanghai Siqiang as VIEs under the Financial Accounting Standards Board’s (“FASB”) interpretation on consolidation of variable interest entities. Accordingly, the Company consolidates the results, assets, and liabilities of Xi’an Tianxing, Xi’an Sikaida and Shanghai Siqiang.
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time to complete the underlying transactions. Actual results may differ from these estimates in amounts that may be material to the consolidated financial statements and accompanying notes. Significant estimates and assumptions made by the Company are used for, but not limited to the allowance for uncollectible receivables, obsolescence reserve against inventory, useful lives of property, plant and equipment and intangible assets, assumptions used in assessing impairment for long-lived assets and the fair value for derivative instruments.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign currency translation
	The Company uses the United States dollar (“U.S. dollar”) for financial reporting purposes and the Chinese Renminbi (“RMB”) as its functional currency. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency, being the primary currency of the economic environment in which their operations are conducted.
	The Company translates the subsidiaries’ and VIEs’ assets and liabilities into U.S. dollars using the applicable exchange rates prevailing at the balance sheet dates, and the statements of comprehensive income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the subsidiaries’ and VIEs’ financial statements are recorded as accumulated other comprehensive income.
	The quotation of the exchange rates does not imply free convertibility of RMB to other foreign currencies. All foreign exchange transactions continue to take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rate quoted by the People’s Bank of China.
	Approval of foreign currency payments by the People’s Bank of China or other institutions requires submitting a payment application form together with invoices, shipping documents, and signed contracts. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair values of financial instruments
	ASC Topic 820, Fair Value Measurement and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. Certain current assets and current liabilities are financial instruments.  Management believes their carrying amounts are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and, if applicable, their current interest rates are equivalent to interest rates currently available. The three levels of valuation hierarchy are defined as follows:
		¨	Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
		¨	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
		¨	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013 and 2012:
			Carrying
			Value at		Fair Value Measurement at
			December 31,		September 30, 2013
			2013		Level 1		Level 2		Level 3
	Purchase option liability		$	62,440	$	—	$	62,440	$	—
			Carrying
			Value at		Fair Value Measurement at
			December 31,		December 31, 2012
			2012		Level 1		Level 2		Level 3
	Purchase option liability		$	5,600	$	—	$	5,600	$	—
	Below is the reconciliation for the purchase option liability:
			December 31,		December 31,
			2013		2012
	Balance, beginning of year		$	5,600	$	43,400
	Change in fair value			56,840		-37,800
	Balance, end of year		$	62,440	$	5,600
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue recognition
	Revenue of the Company is primarily derived from the sales of veterinary healthcare and medical care products in China. Sales are recognized when the following four revenue criteria are met: persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable, and collectability is reasonably assured. Sales are presented net of value added tax (“VAT”). No estimated allowance for sales returns is reflected in these consolidated financial statements as sales returns historically have been insignificant.
	There are two types of sales upon which revenue is recognized:
		a.	Credit sales: revenue is recognized when the products have been delivered to the customers.
		b.	Full payment before delivery: Cash received is recorded as “deposits from customers” and revenue is recognized when the products have been delivered to the customers.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash
	Cash includes currency on hand and demand deposits with banks with an original maturity of three months or less.
Receivables, Policy [Policy Text Block]	'
	Accounts receivable
	Accounts receivable are stated at cost, net of an allowance for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses, if any, resulting from the failure of customers to make required payments. The Company reviews the accounts receivable on a periodic basis and makes allowances where there is doubt as to the collectibility of individual balances. In evaluating the collectibility of individual receivable balances, the Company considers many factors, including the age of the balance, the customer’s payment history, its current credit-worthiness and current economic trends.
Inventory, Policy [Policy Text Block]	'
	Inventories
	Inventories are stated at the lower of cost as determined on a weighted-average basis, or market. Inventories include purchases and related costs incurred in bringing the inventories to their present location and condition. Management reviews inventories for obsolescence and cost in excess of net realizable value and records a write-down  against the inventory and additional cost of goods sold when the carrying value exceeds net realizable value.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property, plant and equipment
	Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses, if any. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs that do not improve or extend the useful lives of the assets are charged to operations as incurred, while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. Estimated useful lives of the assets are as follows:
			Estimated useful life
	Buildings and improvements		Shorter of lease
			term or 10-40 years
	Machinery and equipment		5-10 years
	Office equipment and furniture		3-10 years
	Vehicles		5-10 years
	Management assesses the carrying value of property, plant and equipment annually or more often when factors indicating impairment are present, and reduce the carrying value of such assets by the amount of the impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted) and comparing such amount to the net asset carrying value. An impairment loss, if it exists, is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. Based on its review, management believes that, as of December 31, 2013 and 2012, there was no impairment of its property, plant and equipment.
Construction In Progress Policy [Policy Text Block]	'
	Construction-in-progress
	Construction-in-progress includes direct costs of construction of factory buildings. Interest incurred during the period of construction, if significant, is capitalized. All other interest is expensed as incurred. Construction-in-progress is not depreciated until such time as the asset is completed and put into service.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	'
	Intangible assets
	Land use rights — Land use rights represent the amounts paid to acquire a long-term interest to utilize the land underlying the Company’s facilities. This type of arrangement is common for the use of land in the PRC. Land use rights are amortized on the straight-line method over the contractual lease terms.  The land use right granted to the Company’s Huxian facility was for 50 years.  The land use right granted to the Company’s Jingzhou facility was 30 years. The land use right granted to the Company’s Kunshan facility was for 41 years.
	Technological know-how — Purchased technological know-how includes confidential formulas, manufacturing processes, and technical and procedural manuals, and is amortized using the straight-line method over an estimated useful life of between five to eleven years that reflects the period over which such confidential formulas, manufacturing processes, and technical and procedural manuals are kept confidential by the Company as agreed between the Company and the selling parties.
	Impairment of intangible assets —Intangible assets are evaluated at least annually for impairment if events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Based on the existence of one or more indicators of impairment, the Company measures any impairment of long-lived assets by comparing the asset's estimated fair value with its carrying value, based on cash flow methodology. Based on its review, the Company believes that, as of December 31, 2013 and 2012, there was no impairment of its intangible assets.
Comprehensive Income, Policy [Policy Text Block]	'
	Comprehensive income
	Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income is comprised of the foreign currency translation adjustments.
Shipping and Handling Cost, Policy [Policy Text Block]	'
	Shipping and handling costs
	Shipping and handling costs related to costs of goods sold are included in selling expenses, which totaled $1,792,455 and $1,802,654 for the years ended December 31, 2013 and 2012, respectively.
Advertising Costs, Policy [Policy Text Block]	'
	Advertising costs
	Advertising costs are charged to selling expenses as incurred. Advertising costs were insignificant for the years ended December 31, 2013 and 2012, respectively.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and development costs
	Research and development costs are charged to expenses as incurred and include salaries, professional fees, and material costs and technical support fees related to such efforts.
Income Tax, Policy [Policy Text Block]	'
	Income taxes
	The Company accounts for income taxes using an asset and liability method.  Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred income taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized.
	A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. As of December 31, 2013 and 2012, there are no unrecognized tax benefits, and the Company does not expect a significant change in tax benefits in the next 12 months.  Penalties and interest levied by taxing authorities, if any, are classified as income tax expense in the year incurred. No significant penalties or interest relating to income taxes have been incurred during the years ended December 31, 2013 and 2012.
	According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational or other errors made by the taxpayer or the withholding agent.  The statute of limitations extends to five years under special circumstances. In the case of transfer pricing issues, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. Accordingly, the income tax returns of the Company’s PRC operating subsidiaries for the years ended December 31, 2008 through 2013 are open to examination by the PRC state and local tax authorities.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-based compensation
	The Company records and reports stock-based compensation by measuring the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which services are received. Stock compensation for stock granted to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings per share
	Basic earnings per share is based upon the weighted-average number of common shares outstanding. Diluted earnings per share is based on the assumption that all dilutive convertible shares, including convertible preferred shares, warrants and stock options were converted or exercised. Further, the method requires that stock dividends or stock splits be accounted for retroactively if the stock dividends or stock splits occur during the period or after the end of the period but before the release of the financial statements, by considering it outstanding for the entirety of each period presented. Diluted earnings per share is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.
Related Party [Policy Text Block]	'
	Related parties
	Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of such principal owners and management, and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Operating Segments [Policy Text Block]	'
	Operating segments
	While the chief operating decision-makers monitor the revenue streams of the various products lines, operations are managed and financial performance is evaluated on a Company-wide basis. Product lines are aggregated into one as operating results for all product lines are similar. Accordingly, all of the major product lines (micro-organism, veterinary medicine, feed additives and vaccines) are considered by management to be aggregated in one reportable operating segment.
	As the Company primarily generates its revenues from customers in the PRC, no geographical segments are presented.
Reclassification, Policy [Policy Text Block]	'
	Reclassifications
	Certain amounts included in the 2012 financial statements have been reclassified to conform to the 2013 financial statement presentation as follows:
	The Company has separately presented interest income of $97,591 on the face of consolidated statements of comprehensive income for the year ended December 31, 2012, instead of presented as part of other income, net of $39,933 and interest expenses, net of $57,658.
	As a result of such reclassification, other income, net for the year ended December 31, 2012 has changed from $498,614 to $458,681 and interest expense, net has changed from $706,842 to $764,500.
	The change in deferred government grant of $190,380 and due to related parties of $743,755 were classified into cash flows from financing activities in the Company’s consolidated statement of cash flows for the year ended December 31, 2012. The Company has reclassified these amounts as components of cash flows to operating activities.
	As a result of such reclassification, net cash used in financing activities for the year ended December 31, 2012 has changed from $779,285 to $1,713,420, and net cash provided by operating activities has changed from $5,612,124 to $6,546,259.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently issued accounting pronouncements
	In February 2013, the FASB issued Accounting Standards Update No. 2013-02 Comprehensive Income (Topic 220): The objective of this update is to improve the reporting of reclassifications out of accumulated other comprehensive income. The amendments in this update seek to attain that objective by requiring an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under U.S. generally accepted accounting principles (GAAP) to be reclassified in its entirety to net income. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under U.S. GAAP that provide additional detail about those amounts. This would be the case when a portion of the amount reclassified out of accumulated other comprehensive income is reclassified to a balance sheet account (for example, inventory) instead of directly to income or expense in the same reporting period. For public entities, the amendments are effective prospectively for reporting periods beginning after December 15, 2012. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2013-05, Foreign Currency Matters, (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (ASU 2013-05), to resolve a diversity in accounting for the cumulative translation adjustment of foreign currency upon derecognition of a foreign subsidiary or group of assets. ASU 2013-05 requires the parent to apply the guidance in Subtopic 830-30 to release any related cumulative translation adjustment into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. Further, ASU 2013-05 clarified that the parent should apply the guidance in subtopic 810-10 if there is a sale of an investment in a foreign entity, including both (1) events that result in the loss of a controlling financial interest in a foreign entity and (2) events that result in an acquirer obtaining control of an acquiree in which it held an equity interest immediately before the acquisition date. Accordingly, the cumulative translation adjustment should be released into net income upon the occurrence of those events. ASU 2013-05 is effective prospectively for the Company in our first quarter of fiscal 2014, with early adoption permitted. The Company does not expect ASU 2013-05 to have a significant impact on its consolidated results of operations and financial condition.
	In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Income Taxes (Topic 740)(ASU 2013-11). The amendments in this update provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. These amendments provide that an unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except to the extent that a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date to settle any additional income taxes that would result from disallowance of a tax position, or the tax law does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, then the unrecognized tax benefit should be presented as a liability. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company does not expect ASU 2013-11 to have a significant impact on its consolidated results of operations and financial condition.
	Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013 and 2012:
		Carrying
		Value at		Fair Value Measurement at
		December 31,		September 30, 2013
		2013		Level 1		Level 2		Level 3
	Purchase option liability	$	62,440	$	—	$	62,440	$	—
		Carrying
		Value at		Fair Value Measurement at
		December 31,		December 31, 2012
		2012		Level 1		Level 2		Level 3
	Purchase option liability	$	5,600	$	—	$	5,600	$	—
Schedule Of Reconciliation For Warrant Or Purchase Option Liabilities [Table Text Block]	'
	Below is the reconciliation for the purchase option liability:
		December 31,		December 31,
		2013		2012
	Balance, beginning of year	$	5,600	$	43,400
	Change in fair value		56,840		-37,800
	Balance, end of year	$	62,440	$	5,600
Schedule Of Estimated Useful Lives Of Assets [Table Text Block]	'
	Gains and losses on disposals are included in the results of operations. Estimated useful lives of the assets are as follows:
		Estimated useful life
	Buildings and improvements	Shorter of lease
		term or 10-40 years
	Machinery and equipment	5-10 years
	Office equipment and furniture	3-10 years
	Vehicles	5-10 years

ACCOUNTS_RECEIVABLE_NET_Tables

ACCOUNTS RECEIVABLE, NET (Tables)	12 Months Ended
	Dec. 31, 2013
Accounts Receivable Disclosure [Abstract]	'
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	'
	Accounts receivable consisted of the following:
		December 31,		December 31,
		2013		2012
	Accounts receivable	$	11,611,741	$	10,258,065
	Allowance for doubtful accounts		-602,243		-247,269
	Accounts receivable, net	$	11,009,498	$	10,010,796
Schedule Of Movement In Allowance For Doubtful Accounts [Table Text Block]	'
	The following table presents the movement of the allowance for doubtful accounts:
		December 31,		December 31,
		2013		2012
	Beginning of year	$	247,269	$	438,678
	Addition		1,335,664		166,276
	Reversal		-993,041		-361,247
	Translation adjustment		12,351		3,562
	End of year	$	602,243	$	247,269

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories consist of the following:
		December 31,		December 31,
		2013		2012
	Raw materials	$	23,001,461	$	20,428,757
	Packaging materials		396,067		220,078
	Work-in-process		23,140		219
	Finished goods		2,409,083		2,243,226
	Other		73,835		69,929
	Total	$	25,903,586	$	22,962,209

DEPOSITS_PREPAID_EXPENSES_AND_1

DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	12 Months Ended
	Dec. 31, 2013
Deposits and Prepaid Expenses Disclosure [Abstract]	'
Schedule Of Deposits and Prepaid Expenses [Table Text Block]	'
	Deposits, prepaid expenses and other receivables are comprised of the following:
		December 31,		December 31,
		2013		2012
	Prepaid income taxes	$	-	$	1,263,845
	Other prepayments		478,144		828,676
	Deposits placed with guarantors (note 13)		491,100		198,375
	Interest receivable (note 7)		497,844		-
	Other receivables		667,075		548,954
	Total	$	2,134,163	$	2,839,850

PREPAYMENTS_TO_SUPPLIERS_Table

PREPAYMENTS TO SUPPLIERS (Tables)	12 Months Ended
	Dec. 31, 2013
Prepayments For Raw Materials Purchasing [Abstract]	'
Prepayments For Raw Materials Purchasing [Table Text Block]	'
	Prepayments to suppliers are comprised of the following:
		December 31,		December 31,
		2013		2012
	Prepayments for raw materials	$	39,937,944	$	23,053,753
	Prepayments for packaging materials		1,123,200		384,982
	Total	$	41,061,144	$	23,438,735

PROPERTY_PLANT_AND_EQUIPMENT_N1

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property, plant and equipment consist of the following:
		December 31,			December 31,
		2013			2012
	Buildings and improvements	$	27,703,872		$	27,210,008
	Machinery and equipment		6,093,533			5,876,467
	Office equipment and furniture		337,688			332,653
	Vehicles		611,989			593,296
	Total		34,747,082			34,012,424
	Less: accumulated depreciation		(6,477,927	)		(5,144,608	)
	Property, plant and equipment, net	$	28,269,155		$	28,867,816

CONSTRUCTIONINPROGRESS_Tables

CONSTRUCTION-IN-PROGRESS (Tables)	12 Months Ended
	Dec. 31, 2013
Construction In Progress Disclosure [Abstract]	'
Schedule Of Construction In Progress [Table Text Block]	'
	The construction projects the Company was in the progress of completing are as follows:
		Total in CIP
		as of
	Project	December 31,		Estimated Cost to		Estimated		Estimated
		2013		Complete		Total Cost		Completion Date
	Xi'an vaccine facility	$	2,484,212	$	-	$	2,484,212	Completed, Operational – Third quarter of 2014
	Xi'an animal laboratory		327,400		-		327,400	Completed, Operational – Third quarter of 2014
	Jingzhou veterinary medication facility		1,213,508		505,342		1,718,850	Fourth quarter of 2014
	Kunshan micro-organism facility		5,259,827		7,366,500		12,626,327	Construction - completed, Installation of machinery and
								equipment – Third quarter of 2014
	Total	$	9,284,947	$	7,871,842	$	17,156,789

LONGTERM_PREPAYMENTS_Tables

LONG-TERM PREPAYMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Long Term Prepayments Disclosure [Abstract]	'
Schedule Of Long Term Prepayments [Table Text Block]	'
	Long-term prepayments consist of the following:
		December 31,		December 31,
		2013		2012
	Deposits for equipment purchase and land use rights	$	3,871,228	$	311,227
	Prepayments for R&D projects		366,688		355,488
	Construction deposits		389,556		377,657
	Deposits for other		6,142		5,955
	Long-term prepayments - total	$	4,633,614	$	1,050,327
	Long-term prepayments for acquisitions	$	183,344	$	177,744

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Intangible assets consist of the following
		December 31,		December 31,
		2013		2012
	Land use rights	$	4,951,927	$	4,800,677
	Technological know-how		2,291,800		2,221,800
	Patents		327,400		317,400
	Total		7,571,127		7,339,877
	Less: accumulated amortization		-2,333,872		-2,020,046
	Intangible assets, net	$	5,237,255	$	5,319,831
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Amortization expense expected for the next five years and thereafter is as follows:
	Years ending December 31,	Amount
	2014	$	250,182
	2015		250,182
	2016		250,182
	2017		250,182
	2018		250,182
	Thereafter		3,986,345
	Total	$	5,237,255

SHORTTERM_AND_LONGTERM_LOANS_T

SHORT-TERM AND LONG-TERM LOANS (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule Of Outstanding Short-Term Loans [Table Text Block]	'
	Outstanding short-term loans consisted of the following:
			December 31, 2013					December 31, 2012							Interest
	Bank		Amt RMB		Amt USD			Amt RMB		Amt USD			Due Date		Rate
	ICBC Songzi Branch		-		$	-		3,000,000		$	476,100		6/18/13		-1
	Xi'an High-tech Zone Guoxin Microcredit Ltd.		-			-		15,000,000			2,380,500		2/12/13		22.4	%
	Chang’an Bank		-			-		10,000,000			1,587,000		8/26/13		-1
	Industrial Bank Co. Ltd. Xi’an Branch		30,000,000			4,911,000		-			-		1/15/14		6.6	%
	Postal Savings Bank of China Xi’an Branch		20,000,000			3,274,000		-			-		5/26/14		-2
	ICBC Songzi Branch		5,000,000			818,500		-			-		6/19/14		-1
	Related-party Individual – Chairman and CEO		10,000,000			1,637,000		-			-		9/11/14		7.8	%
	Total		65,000,000		$	10,640,500		28,000,000		$	4,443,600
		-1	People's Bank of China floating benchmark lending rate over the same period plus 30%, which was 7.8% at December 31, 2013.
		-2	People's Bank of China floating benchmark lending rate over the same period plus 20%, which was 7.2% at December 31, 2013.
Schedule Of Outstanding Long Term Loans [Table Text Block]	'
	Outstanding long-term loan consisted of the following:
			December 31, 2013						December 31, 2012							Interest
	Bank		Amt RMB			Amt USD			Amt RMB		Amt USD			Due Date		Rate
	Shaanxi Agricultural Yanta Credit Union			-			-		8,000,000		$	1,269,600		9/20/14			9.446	%
	Total			-		$	-		8,000,000		$	1,269,600

CAPITAL_TRANSACTIONS_Tables

CAPITAL TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of Nonvested Share Activity [Table Text Block]	'
	A summary of changes in the Company’s non-vested shares for the year follows:
		Non-vested Shares
	Non-vested at January 1, 2012		17,000
	Granted		13,556
	Vested		-24,556
	Forfeited		-
	Non-vested at December 31, 2012		6,000
	Granted		69,556
	Vested		-62,556
	Forfeited		-
	Non-vested at December 31, 2013		13,000
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	Outstanding purchase options do not trade in an active securities market, and as such, the Company estimates the fair value of these purchase options using the Black-Scholes Option Pricing Model (“Black-Scholes Model”) using the following assumptions:
		Purchase Options
		December 31,				December 31,
		2013				2012
	Stock price	$	3.51			$	1.6
	Exercise price	$	8.11			$	8.11
	Annual dividend yield		-				-
	Expected term (years)		0.5				1.5
	Risk-free interest rate		0.1	%			0.16	%
	Expected volatility		125	%			73	%
	Option value	$	0.45			$	0.04
Schedule Of Share Based Compensation Warrants and Purchase Options Activity [Table Text Block]	'
	Following is an activity summary of the Company’s outstanding purchase options:
		Number of		Weighted –			Weighted-
		purchase		average			average
		options		exercise price			remaining
							contractual term
							(Year)
	Outstanding at January 1, 2011	174,230		$	7.5		2.04
	Granted	-
	Forfeited	-34,230			5
	Exercised	-
	Outstanding at December 31, 2012	140,000		$	8.11		1.5
	Granted	-
	Forfeited	-
	Exercised	-
	Outstanding at December 31, 2013	140,000		$	8.11		0.5
	Exercisable at December 31, 2013	140,000		$	8.11		0.5

TAXES_Tables

TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Taxes Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	Provision for income taxs consisted of the following:
	PRC income taxes		December 31,		December 31,
			2013		2012
	Current		$	2,760,936	$	2,168,125
	Deferred			-359,628		-
	Total		$	2,401,308	$	2,168,125
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The following table reconciles the U.S. statutory rates to the Company’s effective tax rate for the years ended December 31, 2013 and 2012:
			Years ended December 31,
			2013		2012
	U.S. Statutory rate		34	%	34	%
	Foreign income not recognized in the U.S.		-34		-34
	China income tax rate		25		25
	China income tax exemption		-10		-10
	Other item (1)		3.6		10.9
	Total provision for income taxes		18.6	%	25.9	%
		-1	Other items are primarily for operating expenses (income) incurred by Skystar that are not deductible (taxable) in the PRC, expenses incurred by other subsidiaries that are not deductible on the consolidated level, the difference of taxable income under US GAAP rather than Chinese GAAP, and the difference of Enterprise Income Tax imposed at a statutory rate of 25% rather than preferential tax rate of 15% on the income from the subsidiaries other than Xi’an Tianxing, which resulted in an increase in the effective tax rate of 3.6% and 10.9% for the years ended December 31, 2013 and 2012, respectively.
Income Tax Rate Reconciliation Other Adjustments [Table Text Block]	'
	Other items consisted of the following:
		Years ended December 31,
		2013			2012
	Income taxed at Chinese statutory rate of 25%		0.2	%		4.4	%
	Valuation allowance on tax loss		1.5			1.8
	Non-deductible operating expenses		1.9			4.7
	Total other items		3.6	%		10.9	%
Schedule Of Taxes Payable [Table Text Block]	'
	Taxes payable consisted of the following:
			December 31,		December 31,
			2013		2012
	Income taxes		$	662,811	$	279,680
	Value added taxes			576,603		1,409,762
	Other taxes			76,072		261,315
	Total		$	1,315,486	$	1,950,757

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The earnings per share are as follows:
		Years ended December 31,
		2013		2012
	Net income	$	10,530,252	$	6,212,428
	Weighted average shares used in basic computation		7,651,640		7,471,350
	Effect of dilutive potential non-vested common shares		4,446		-
	Weighted average shares used in diluted computation		7,656,086		7,471,350
	Earnings per share:
	Basic	$	1.38	$	0.83
	Diluted	$	1.37	$	0.83

RELATED_PARTY_TRANSACTIONS_AND1

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
	Amounts receivable from and payable to related parties are summarized as follows:
			December 31,		December 31,
			2013		2012
	Amounts due to related parties
	Weibing Lu – CEO (1)		$	857,012	$	608,282
	Bing Mei – CFO (2)			41,283		264
	Scott Cramer – non-executive director and shareholder (2)			300,203		138,169
	Directors, shareholders and other related parties (3)			163,050		52,210
	Total		$	1,361,548	$	798,925
		-1	As of December 31, 2013 and 2012, the Company had unpaid reimbursement, compensation, and advances for business expenses due to Weibing Lu valued at $857,012 and $608,282, respectively.
		-2	As of December 31, 2013 and 2012, the Company had unpaid reimbursement and compensation due to Scott Cramer valued at $300,203 and $138,169, respectively. On March 10, 2014, the Board of Directors, including all of the independent members of the Board, reviewed and approved the terms of Mr. Cramer’s Consulting Services Agreement with the Company pursuant to which the Company would continue employing him as its US representative in consideration of (i) a quarterly cash fee of $7,500, (ii) 7,000 restricted shares of the Company’s common stock issuable on a quarterly basis pursuant to the Company’s 2010 Stock Incentive Plan, and (iii) reimbursement of out of pocket expenses.  In addition, Mr. Cramer agreed to pay certain invoices of the Company to its vendors (and the Company agreed to reimburse Mr. Cramer) in the form of a no interest bearing loan in the aggregate amount of approximately $250,000.  As of December 31, 2013 and 2012, the Company had unpaid reimbursement and compensation due to Bing Mei valued at $41,283 and $264, respectively.
		-3	The amounts due to directors, shareholders and other related parties at December 31, 2013 and 2012 include unpaid reimbursement and advances to other related parties for business expenses.

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	The minimum future lease payments for the next five years and thereafter are as follows:
	Period	Unrelated third		Related parties		Total
		parties
	Year ending December 31, 2014	$	52,291	$	53,039	$	105,330
	Year ending December 31, 2015		8,840		53,039		61,879
	Year ending December 31, 2016		8,840		53,039		61,879
	Year ending December 31, 2017 and thereafter		2,210		13,751		15,961
	Total	$	72,181	$	172,868	$	245,049
Schedule Of Research and Development Project Costs [Table Text Block]	'
	R&D projects are summarized as follows:
	Project	Amount		Amount		Total amount
		incurred as		expected to be		of
		of 12/31/2013		incurred		project
	Project with Northwestern Agricultural Technology University
	Application of nano-technology in the prevention of major milk cow disease	$	572,950	$	81,850	$	654,800
	Project with the Fourth Military Medical University
	Fish diseases linked immunosorbent detection kit and fish diseases Multi-linked monoclonal antibody therapeutic agents		851,240		130,960		982,200
	New treatment and diagnosis method for Mycoplasmal pneumonia of swine		245,550		81,850		327,400
	Transfer factor test		50,747		-		50,747
	In-house R&D project during 2012
	Oral liquid products R&D and field trials		163,700		-		163,700
	Powder for injection products R&D and field trials		163,700		-		163,700
	Vitamin E injection product development		81,850		-		81,850
	Anthelmintic product development		81,850		-		81,850
	Three disease grams product development		81,850		-		81,850
	Premixes class product development		81,850		-		81,850
	Bulk powder products development		81,850		-		81,850
	Livestock and fish diseases immunoassay kit development		409,250		-		409,250
	In-house R&D project during 2013
	Fish monoclonal antibody vaccine		491,100		81,850		572,950
	Livestock and avian disease multi-joint yolk antibody therapeutic agents		327,400		392,880		720,280
	Other projects for veterinary products formula adjustment, pet drug development, fermentation engineering design and development, GMP inspection trial production tests and other lab tests		1,676,100		16,370		1,692,470
	Total	$	5,360,987	$	785,760	$	6,146,747
Long-term Purchase Commitment [Table Text Block]	'
	The Company’s commitments for capital expenditure as of December 31, 2013 are as follows:
	Contracted but not accrued for:
	Purchase of machinery and construction (Note 9)	$	4,358,840

SEGEMENT_INFORMATION_Tables

SEGEMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The Company’s revenues and cost of revenues by product line were as follows:
		Years Ended December 31,
		2013		2012
	Revenues
	Veterinary Medications	$	25,515,844	$	10,658,359
	Micro-organism		13,546,118		15,355,467
	Feed Additives		1,790,981		4,021,567
	Vaccines		1,630,773		3,551,398
	Total Revenues	$	42,483,716	$	33,586,791
	Cost of Revenues
	Veterinary Medications	$	15,181,929	$	6,087,300
	Micro-organism		4,119,721		5,498,463
	Feed Additives		1,365,794		3,074,301
	Vaccines		325,518		434,940
	Total Cost of Revenues		20,992,962		15,095,004
	Gross Profit	$	21,490,754	$	18,491,787

PARENT_COMPANY_STATEMENTS_OF_O

PARENT COMPANY STATEMENTS OF OPERATIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Condensed Income Statement [Table Text Block]	'
	PARENT COMPANY STATEMENTS OF OPERATIONS
		Years ended December 31,
		2013		2012
	REVENUE, net	$	-	$	-
	OPERATING EXPENSES:
	Salaries and consulting expenses		384,513		272,660
	General and administrative		836,098		1,819,709
	Total operating expenses		1,220,611		2,092,369
	LOSS FROM OPERATIONS		-1,220,611		-2,092,369
	OTHER INCOME (EXPENSE):
	Change in fair value of purchase option liability		-56,840		37,800
	Other income		-		13,819
	Total other income (expense), net		-56,840		51,619
	(LOSS) ATTRIBUTABLE TO PARENT COMPANY		-1,277,451		-2,040,750
	EQUITY IN EARNINGS OF SUBSIDIARIES		11,807,703		8,253,178
	NET INCOME AVAILABLE TO SHAREHOLDERS	$	10,530,252	$	6,212,428

PARENT_COMPANY_BALANCE_SHEETS_

PARENT COMPANY BALANCE SHEETS (Tables)	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Condensed Balance Sheet [Table Text Block]	'
	PARENT COMPANY BALANCE SHEETS
		December 31,		December 31,
		2013		2012
	ASSETS
	CURRENT ASSETS:
	Cash	$	920	$	968
	Prepaid expenses and other current assets		258,370		283,836
	Total current assets		259,290		284,804
	Interests in subsidiaries		111,331,905		96,750,650
	Total assets	$	111,591,195	$	97,035,454
	LIABILITIES AND SHAREHOLDERS' EQUITY
	CURRENT LIABILITIES:
	Accounts payable and accrued expenses	$	120,720	$	126,062
	Salary and consulting fees payable		71,972		71,838
	Due to related parties		943,087		617,021
	Total current liabilities		1,135,779		814,921
	OTHER LIABILITIES:
	Purchase option liability		62,440		5,600
	Total liabilities		1,198,219		820,521
	SHAREHOLDERS' EQUITY		110,392,976		96,214,933
	Total liabilities and shareholders' equity	$	111,591,195	$	97,035,454

PARENT_COMPANY_STATEMENTS_OF_C

PARENT COMPANY STATEMENTS OF CASH FLOWS (Tables)	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Condensed Cash Flow Statement [Table Text Block]	'
	PARENT COMPANY STATEMENTS OF CASH FLOWS
		Years ended December 31,
		2013		2012
	CASH FLOWS FROM OPERATING ACTIVITIES:
	Net income available to shareholders	$	10,530,252	$	6,212,428
	Adjustments to reconcile net income to net cash used in operating activities:
	Equity in earnings of subsidiaries		-11,807,703		-8,253,178
	Common stock to be issued to related parties for compensation		143,549		86,162
	Common stock issued under 2010 stock incentive plan		-		1,037,911
	Change in fair value of purchase option liability		56,840		-37,800
	Change in operating assets and liabilities
	Prepaid expenses and other current assets		25,466		-27,836
	Accounts payable and accrued expenses		-5,342		-401,077
	Salary and consulting fees payable		134		-273,050
	Increase in due to related parties		565,496		326,630
	Net cash used in operating activities		-491,308		-1,329,810
	CASH FLOWS FROM INVESTING ACTIVITIES:
	Decrease in interest in subsidiaries		491,260		1,318,270
	Net cash provided by investing activities		491,260		1,318,270
	CASH FLOWS FROM FINANCING ACTIVITIES:
	Net cash provided by financing activities		-		-
	DECREASE IN CASH		-48		-11,540
	CASH, beginning of year		968		12,508
	CASH, end of year	$	920	$	968

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012
				Fair Value, Inputs, Level 1 [Member]	Fair Value, Inputs, Level 1 [Member]	Fair Value, Inputs, Level 2 [Member]	Fair Value, Inputs, Level 2 [Member]	Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'	'	'	'	'
Purchase option liability	$62,440	$5,600	$43,400	$0	$0	$62,440	$5,600	$0	$0

ORGANIZATION_Details_Textual

ORGANIZATION (Details Textual)	Apr. 21, 2010	Apr. 21, 2010	7-May-10	Apr. 21, 2010	Apr. 21, 2010	Feb. 05, 2010	Feb. 05, 2010	Mar. 15, 2011	Mar. 15, 2011
	Xian Tianxing [Member]	Xian Tianxing [Member]	Kunshan Sikeda Biotechnology Co Ltd [Member]	Kunshan Sikeda Biotechnology Co Ltd [Member]	Kunshan Sikeda Biotechnology Co Ltd [Member]	Skystar Biotechnology (Kunshan) Co., Limited [Member]	Skystar Biotechnology (Kunshan) Co., Limited [Member]	Xian Sikaida Bio-products Co., Ltd. [Member]	Xian Sikaida Bio-products Co., Ltd. [Member]
	USD ($)	CNY	USD ($)	USD ($)	CNY	USD ($)	CNY	USD ($)	CNY
Organization [Line Items]	'	'	'	'	'	'	'	'	'
Capital	$40,925	250,000	$15,000,000	$81,850	500,000	$4,300,000	26,000,000	$1,637,000	10,000,000
Capital Required to be Well Capitalized	'	'	12,750,000	'	'	'	'	'	'
Capital Contribution In Cash	'	'	$2,250,000	'	'	'	'	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Purchase Option Liability [Line Items]	'	'
Balance, beginning of year	$5,600	$43,400
Change in fair value	56,840	-37,800
Balance, end of year	$62,440	$5,600

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Dec. 31, 2013
Building and Building Improvements [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'10 years
Building and Building Improvements [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'40 years
Machinery and Equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'5 years
Machinery and Equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'10 years
Office equipment and furniture [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'3 years
Office equipment and furniture [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'10 years
Vehicles [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'5 years
Vehicles [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'10 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Significant Accounting Policies [Line Items]	'	'
Shipping, Handling and Transportation Costs	$1,792,455	$1,802,654
Interest Income, Other	539,587	97,591
Other Nonoperating Income (Expense)	48,401	458,681
Interest Expense	'	764,500
Increase Decrease In Deferred Government Grants	-452,340	190,380
Increase (Decrease) in Due to Related Parties, Total	'	743,755
Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total	4,684,950	-1,713,420
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	-5,423,380	6,546,259
Percentage Of Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Settlement	50.00%	'
Reclassification [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Other Nonoperating Income	'	39,933
Interest Expense	'	57,658
Scenario, Previously Reported [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Other Nonoperating Income (Expense)	'	498,614
Interest Expense	'	706,842
Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total	'	779,285
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	'	$5,612,124
Land Use Right [Member] | Huxian Facility [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'50 years	'
Land Use Right [Member] | Jingzhou Facility [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'30 years	'
Land Use Right [Member] | Kunshan Facility [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'41 years	'

CONCENTRATIONS_AND_CREDIT_RISK1

CONCENTRATIONS AND CREDIT RISK (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Concentration Risk [Line Items]	'	'
Due To Related Parties, Current	$1,361,548	$798,925
Supplier Concentration Risk [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	89.00%	82.00%
Due To Related Parties, Current	$32,094,767	$20,092,101
Product Concentration Risk [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	13.00%	15.00%

ACCOUNTS_RECEIVABLE_NET_Detail

ACCOUNTS RECEIVABLE, NET (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule of Financing Receivable [Line Items]	'	'	'
Accounts receivable	$11,611,741	$10,258,065	'
Allowance for doubtful accounts	-602,243	-247,269	-438,678
Accounts receivable, net	$11,009,498	$10,010,796	'

ACCOUNTS_RECEIVABLE_NET_Detail1

ACCOUNTS RECEIVABLE, NET (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule of Financing Receivable [Line Items]	'	'
Beginning of year	$247,269	$438,678
Addition	1,335,664	166,276
Reversal	-993,041	-361,247
Translation adjustment	12,351	3,562
End of year	$602,243	$247,269

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory [Line Items]	'	'
Raw materials	$23,001,461	$20,428,757
Packaging materials	396,067	220,078
Work-in-process	23,140	219
Finished goods	2,409,083	2,243,226
Other	73,835	69,929
Total	$25,903,586	$22,962,209

INVENTORIES_Details_Textual

INVENTORIES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Inventory [Line Items]	'	'
Inventory Write-down	$0	$16,026

DEPOSITS_PREPAID_EXPENSES_AND_2

DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deposits and Prepaid Expenses [Line Items]	'	'
Prepaid income taxes	$0	$1,263,845
Other prepayments	478,144	828,676
Deposits placed with guarantors (note 13)	491,100	198,375
Interest receivable (note 7)	497,844	0
Other receivables	667,075	548,954
Total	$2,134,163	$2,839,850

PREPAYMENTS_TO_SUPPLIERS_Detai

PREPAYMENTS TO SUPPLIERS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Payments To Suppliers [Line Items]	'	'
Prepayments for raw materials	$39,937,944	$23,053,753
Prepayments for packaging materials	1,123,200	384,982
Total	$41,061,144	$23,438,735

PREPAYMENTS_TO_SUPPLIERS_Detai1

PREPAYMENTS TO SUPPLIERS (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Payments To Suppliers [Line Items]	'	'
Unpaid interest income on prepayments to suppliers	$491,305	$0
Payments to Suppliers	31,953,084	'
Interest Rate Charged Annually On Prepayment On Raw Material	2.00%	'
Unpaid Balance To Supplier	$497,844	'

PROPERTY_PLANT_AND_EQUIPMENT_N2

PROPERTY, PLANT AND EQUIPMENT, NET (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Buildings and improvements	$27,703,872	$27,210,008
Machinery and equipment	6,093,533	5,876,467
Office equipment and furniture	337,688	332,653
Vehicles	611,989	593,296
Total	34,747,082	34,012,424
Less: accumulated depreciation	-6,477,927	-5,144,608
Property, plant and equipment, net	$28,269,155	$28,867,816

PROPERTY_PLANT_AND_EQUIPMENT_N3

PROPERTY, PLANT AND EQUIPMENT, NET (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Depreciation	$1,467,261	$1,035,829
Property, Plant and Equipment Pledged Against Loan	$19,969,335	$2,180,382

CONSTRUCTIONINPROGRESS_Details

CONSTRUCTION-IN-PROGRESS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
			Xi' Vaccine Facility [Member]	Xi' Animal Laboratory [Member]	Kunshan Micro Organism Facility [Member]	Jingzhou Veterinary Medication Facility [Member]
Construction In Progress [Line Items]	'	'	'	'	'	'
Total in CIP as of December, 31 2013	$9,284,947	$8,691,360	$2,484,212	$327,400	$5,259,827	$1,213,508
Estimate Cost to Complete	7,871,842	'	0	0	7,366,500	505,342
Estimated Total Cost	$17,156,789	'	$2,484,212	$327,400	$12,626,327	$1,718,850
Estimated Completion Date	'	'	'Completed, Operational – Third quarter of 2014	'Completed, Operational – Third quarter of 2014	'Construction - completed, Installation of machinery and equipment – Third quarter of 2014	'Fourth quarter of 2014

CONSTRUCTIONINPROGRESS_Details1

CONSTRUCTION-IN-PROGRESS (Details Textual) (USD $)	12 Months Ended							9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2013
			Huxian Vaccine Facility [Member]	Huxian Animal Laboratory [Member]	Jingzhou Facility [Member]	Jingzhou Facility [Member]	Kunshan Facility [Member]	Kunshan Micro Organism Facility [Member]	Kunshan Micro Organism Facility [Member]
Construction In Progress [Line Items]	'	'	'	'	'	'	'	'	'
Total in cost in progress	$9,284,947	$8,691,360	$2,484,212	$327,400	$1,213,508	$1,718,850	$5,259,827	'	$5,259,827
Payments to Acquire Machinery and Equipment	'	'	'	'	'	'	'	3,513,002	'
Purchase Price of Machinery And Equipment	'	'	'	'	'	'	'	7,366,500	'
Interest Costs Capitalized	$137,950	$0	'	'	'	'	'	'	'

LOANS_RECEIVABLE_Details_Textu

LOANS RECEIVABLE (Details Textual)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Apr. 01, 2012	Apr. 01, 2012
	USD ($)	USD ($)	Xian Tinantal Investment [Member]	Xian Tinantal Investment [Member]	Shaanxi Jiali Pharmaceutical Co Ltd [Member]	Shaanxi Jiali Pharmaceutical Co Ltd [Member]
			USD ($)	CNY	Unrelated Parties [Member]	Unrelated Parties [Member]
					USD ($)	CNY
Loans Receivables [Line Items]	'	'	'	'	'	'
Notes, Loans and Financing Receivable, Net, Current	$0	$1,078,827	$190,400	1,200,000	$793,500	5,000,000
Interest Rate	'	'	12.00%	12.00%	12.00%	12.00%
Investment Income, Interest	45,880	97,238	'	'	'	'
Non Interest Bearing Unsecured Debt	$0	$94,887	'	'	'	'

LONGTERM_PREPAYMENTS_Details

LONG-TERM PREPAYMENTS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Long Tem Prepayments [Line Items]	'	'
Deposits for equipment purchase and land use rights	$3,871,228	$311,227
Prepayments for R&D project	366,688	355,488
Construction deposits	389,556	377,657
Deposits for other	6,142	5,955
Long-term prepayments - total	4,633,614	1,050,327
Long-term prepayments for acquisitions	$183,344	$177,744

LONGTERM_PREPAYMENTS_Details_T

LONG-TERM PREPAYMENTS (Details Textual) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Long Tem Prepayments [Line Items]	'	'
Deposits for potential acquisitions	$183,344	$177,744

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Total	$7,571,127	$7,339,877
Less: accumulated amortization	-2,333,872	-2,020,046
Intangible assets, net	5,237,255	5,319,831
Land Use Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total	4,951,927	4,800,677
Technical Know How [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total	2,291,800	2,221,800
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total	$327,400	$317,400

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Dec. 31, 2013
Intangible Assets Future Amortization Expense [Line Items]	'
2014	$250,182
2015	250,182
2016	250,182
2017	250,182
2018	250,182
Thereafter	3,986,345
Total	$5,237,255

INTANGIBLE_ASSETS_Details_Text

INTANGIBLE ASSETS (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Intangible Assets [Line Items]	'	'
Amortization	$246,896	$401,114
Use Rights [Member]	'	'
Intangible Assets [Line Items]	'	'
Real Estate and Accumulated Depreciation, Carrying Amount of Land	$1,529,960	$1,199,456

SHORTTERM_AND_LONGTERM_LOANS_D

SHORT-TERM AND LONG-TERM LOANS (Details)

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Aug. 13, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Aug. 13, 2012

Aug. 13, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Aug. 27, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Sep. 17, 2013

USD ($)

CNY

USD ($)

CNY

CNY

Icbc Songzi Branch One [Member]

Icbc Songzi Branch One [Member]

Icbc Songzi Branch One [Member]

Icbc Songzi Branch One [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Changan Bank [Member]

Changan Bank [Member]

Changan Bank [Member]

Changan Bank [Member]

Changan Bank [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Postal Savings Bank of China Xiban Branch [Member]

Postal Savings Bank of China Xiban Branch [Member]

Postal Savings Bank of China Xiban Branch [Member]

Postal Savings Bank of China Xiban Branch [Member]

Icbc Songzi Branch Two [Member]

Icbc Songzi Branch Two [Member]

Icbc Songzi Branch Two [Member]

Icbc Songzi Branch Two [Member]

Related-party Individual - Chairman and CEO [Member]

Related-party Individual - Chairman and CEO [Member]

Related-party Individual - Chairman and CEO [Member]

Related-party Individual - Chairman and CEO [Member]

Shaanxi Agricultural Yanta Credit Union One [Member]

Shaanxi Agricultural Yanta Credit Union One [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

CNY

Short-term Debt [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Bank Loans

$10,640,500

65,000,000

$4,443,600

28,000,000

15,000,000

$0

[1]

0

[1]

$476,100

[1]

3,000,000

[1]

$0

0

$2,380,500

15,000,000

$158,700

1,000,000

$0

[1]

0

[1]

$1,587,000

[1]

10,000,000

[1]

10,000,000

$4,911,000

30,000,000

$0

0

$3,274,000

[2]

20,000,000

[2]

$0

[2]

0

[2]

$818,500

[1]

5,000,000

[1]

$0

[1]

0

[1]

$1,637,000

10,000,000

$0

0

'

8,000,000

Due Date

'

'

'

'

'

18-Jun-13

[1]

18-Jun-13

[1]

'

'

12-Feb-13

12-Feb-13

'

'

'

'

26-Aug-13

[1]

26-Aug-13

[1]

'

'

'

15-Jan-14

15-Jan-14

'

'

26-May-14

[2]

26-May-14

[2]

'

'

19-Jun-14

[1]

19-Jun-14

[1]

'

'

11-Sep-14

11-Sep-14

'

'

20-Sep-14

'

Interest Rate

'

'

'

'

'

'

'

'

'

22.40%

22.40%

'

'

22.40%

22.40%

'

'

'

'

'

6.60%

6.60%

'

'

'

'

'

'

'

'

'

'

7.80%

7.80%

'

'

9.45%

9.45%

[1]

People's Bank of China floating benchmark lending rate over the same period plus 30%, which was 7.8% at December 31, 2013.

[2]

People's Bank of China floating benchmark lending rate over the same period plus 20%, which was 7.2% at December 31, 2013.

SHORTTERM_AND_LONGTERM_LOANS_D1

SHORT-TERM AND LONG-TERM LOANS (Details 1)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Sep. 17, 2013	Dec. 31, 2012	Dec. 31, 2012
	USD ($)	CNY	USD ($)	CNY	Shaanxi Agricultural Yanta Credit Union One [Member]	Shaanxi Agricultural Yanta Credit Union One [Member]	Shaanxi Agricultural Yanta Credit Union One [Member]	Shaanxi Agricultural Yanta Credit Union One [Member]	Shaanxi Agricultural Yanta Credit Union One [Member]
					USD ($)	CNY		USD ($)	CNY
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Long-term loan	$0	0	$1,269,600	8,000,000	$0	0	'	$1,269,600	8,000,000
Due Date	'	'	'	'	20-Sep-14	20-Sep-14	'	'	'
Interest Rate	'	'	'	'	9.45%	9.45%	9.45%	'	'

SHORTTERM_AND_LONGTERM_LOANS_D2

SHORT-TERM AND LONG-TERM LOANS (Details Textual)

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Aug. 13, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 27, 2012

Dec. 31, 2013

Dec. 31, 2013

Jul. 03, 2012

Jul. 03, 2012

Aug. 27, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Sep. 17, 2013

Sep. 17, 2013

Dec. 31, 2013

Sep. 10, 2013

Jun. 13, 2013

Jun. 13, 2013

Jan. 16, 2013

Jan. 16, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Aug. 13, 2012

Aug. 13, 2012

Apr. 16, 2013

Apr. 16, 2013

Aug. 27, 2012

Dec. 31, 2013

Dec. 31, 2013

Aug. 27, 2012

Apr. 16, 2013

Apr. 16, 2013

Dec. 31, 2013

Sep. 10, 2013

Sep. 10, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

USD ($)

USD ($)

CNY

CNY

CNY

Construction in Progress [Member]

Construction in Progress [Member]

Industrial and Commercial Bank Of China Songzi Branch [Member]

Industrial and Commercial Bank Of China Songzi Branch [Member]

Industrial and Commercial Bank Of China Songzi Branch [Member]

Industrial and Commercial Bank Of China Songzi Branch [Member]

Industrial and Commercial Bank Of China Songzi Branch [Member]

Changan Bank [Member]

Changan Bank [Member]

Changan Bank [Member]

Changan Bank [Member]

Changan Bank [Member]

Shaanxi Agricultural Yanta Credit Union One [Member]

Shaanxi Agricultural Yanta Credit Union One [Member]

Shaanxi Agricultural Yanta Credit Union One [Member]

Industrial and Commercial Bank Of China [Member]

Industrial and Commercial Bank Of China [Member]

Industrial and Commercial Bank Of China [Member]

Industrial and Commercial Bank Of China [Member]

Industrial and Commercial Bank Of China [Member]

Industrial and Commercial Bank Of China [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian High Tech Zone Guoxin Microcredit Ltd [Member]

Xian Taixin Investment Guarantee Co Ltd [Member]

Xian Taixin Investment Guarantee Co Ltd [Member]

Xian Taixin Investment Guarantee Co Ltd [Member]

Xian Taixin Investment Guarantee Co Ltd [Member]

Xian Taixin Investment Guarantee Co Ltd [Member]

Xian Taixin Investment Guarantee Co Ltd [Member]

Postal Savings Bank Of China Xi [Member]

Postal Savings Bank Of China Xi [Member]

Postal Savings Bank Of China Xi [Member]

Bank Of Beijing [Member]

Bank Of Beijing [Member]

Bank Of Beijing [Member]

Bank Of Beijing [Member]

Bank Of Beijing [Member]

Bank Of Beijing [Member]

USD ($)

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

CNY

USD ($)

CNY

USD ($)

USD ($)

CNY

Chairman And CEO [Member]

Chairman And CEO [Member]

Chairman And CEO [Member]

Chairman And CEO [Member]

Chairman And CEO [Member]

Chairman And CEO [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Short Term And Long Term [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Bank Loans

10,640,500

4,443,600

65,000,000

28,000,000

15,000,000

'

'

3,000,000

'

'

476,100

3,000,000

10,000,000

0

[1]

0

[1]

1,587,000

[1]

10,000,000

[1]

'

'

8,000,000

'

'

818,500

5,000,000

4,911,000

30,000,000

0

0

2,380,500

15,000,000

158,700

1,000,000

'

'

1,250,000

58,158

360,000

198,375

3,274,000

20,000,000

'

'

'

'

'

'

'

Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.45%

9.45%

9.45%

7.80%

7.80%

'

'

6.60%

6.60%

22.40%

22.40%

'

'

22.40%

22.40%

'

'

'

'

'

12.50%

'

'

7.20%

'

'

7.80%

7.80%

7.80%

7.80%

Cash paid for interest

644,489

647,249

'

'

'

137,950

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fee Paid For Loan Guarantee

'

'

'

'

'

'

'

'

81,850

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

327,400

2,000,000

200,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Description of Variable Rate Basis

'

'

'

'

'

'

'

'People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate

'

'

'

'

'People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'People's Bank of China floating benchmark lending rate over the same period plus 20% of that rate

'People's Bank of China floating benchmark lending rate over the same period plus 20% of that rate

'

'

'

'

'

'

'

Debt Instrument, Collateral Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

163,700

1,000,000

163,700

1,000,000

Debt Instrument, Collateral

'

'

'

'

'

'

'

'

'This loan is secured by the Companys buildings and land use rights in Jingzhou, Hubei Province.

'This loan is secured by the Companys buildings and land use rights in Jingzhou, Hubei Province.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10% of the loan or $327,400 (RMB 2,000,000) is required to be kept by Xian Investment and Financing Guarantee Co., Ltd. to serve as collateral until the loan is repaid. This loan is secured by the Companys office buildings located in Xian

'10% of the loan or $327,400 (RMB 2,000,000) is required to be kept by Xian Investment and Financing Guarantee Co., Ltd. to serve as collateral until the loan is repaid. This loan is secured by the Companys office buildings located in Xian

'

'

'

'

'

'

'

'

'

'

Short-term Bank Loans and Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,637,000

10,000,000

'

'

'

'

Debt Instrument, Interest Rate Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The annual interest rate is determined by using the prime rate over the same period plus 30% of that rate, which was 7.8% at the date that the loan was issued.

'The annual interest rate is determined by using the prime rate over the same period plus 30% of that rate, which was 7.8% at the date that the loan was issued.

'

'

'

'

Debt Issuance Cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$29,079

180,000

Percentage Of Loan Served As Collateral Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

10.00%

10.00%

[1]

People's Bank of China floating benchmark lending rate over the same period plus 30%, which was 7.8% at December 31, 2013.

DEFERRED_GOVERNMENT_GRANT_Deta

DEFERRED GOVERNMENT GRANT (Details Textual)	3 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
	Xian Municipal Government [Member]	Xian Municipal Government [Member]	Xian Municipal Government [Member]	Xian Municipal Government [Member]	Xian Municipal Government [Member]	China Go Xin Investment Group [Member]	China Go Xin Investment Group [Member]
	USD ($)	CNY	USD ($)	CNY	USD ($)	USD ($)	CNY
Deferred Government Grant [Line Items]	'	'	'	'	'	'	'
Proceeds From Government Subsidies	'	'	$409,250	2,500,000	$396,750	'	'
Repayments Of Government Subsidies	196,440	1,200,000	687,540	4,200,000	666,540	'	'
Percentage Repayment Of Government Subsidies	'	'	70.00%	70.00%	'	'	'
Proceeds From Demand Payment	'	'	'	'	'	$491,100	3,000,000

CAPITAL_TRANSACTIONS_Details

CAPITAL TRANSACTIONS (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Nonvested shares [Line Items]	'	'
Non-vested at Beginning	6,000	17,000
Granted	69,556	13,556
Vested	-62,556	-24,556
Forfeited	0	0
Non-vested at Ending	13,000	6,000

CAPITAL_TRANSACTIONS_Details_1

CAPITAL TRANSACTIONS (Details 1) (Purchase Options [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Purchase Options [Member]	'	'
Purchase Options [Line Items]	'	'
Stock price	$3.51	$1.60
Exercise price	$8.11	$8.11
Annual dividend yield	0.00%	0.00%
Expected term (years)	'6 months	'1 year 6 months
Risk-free interest rate	0.10%	0.16%
Expected volatility	125.00%	73.00%
Option value	$0.45	$0.04

CAPITAL_TRANSACTIONS_Details_2

CAPITAL TRANSACTIONS (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Purchase Options [Line Items]	'	'	'
Number of options purchase, Outstanding, beginning balance	140,000	174,230	'
Granted, Number of warrants/purchase options	0	0	'
Forfeited, Number of warrants/purchase options	0	-34,230	'
Exercised, Number of warrants/purchase options	0	0	'
Number of options purchase, Outstanding, ending balance	140,000	140,000	174,230
Exercisable at December 31, 2013, Number of warrants/purchase options	140,000	'	'
Outstanding, Weighted - average exercise price, beginning balance	$8.11	$7.50	'
Forfeited, Weighted - average exercise price	'	$5	'
Outstanding, Weighted - average exercise price, ending balance	$8.11	$8.11	$7.50
Exercisable at December 31, 2013, Weighted - average exercise price	$8.11	'	'
Weighted- average remaining contractual term, outstanding (Year)	'6 months	'1 year 6 months	'2 years 14 days
Exercisable at December 31, 2013, Weighted - average remaining contractual term (Year)	'6 months	'	'

CAPITAL_TRANSACTIONS_Details_T

CAPITAL TRANSACTIONS (Details Textual) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Feb. 28, 2012

Jun. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 08, 2009

4-May-12

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

26-May-09

Jul. 29, 2011

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2011

Mar. 10, 2014

Feb. 28, 2007

Mar. 31, 2014

Mar. 10, 2014

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Non Executive Director [Member]

Non Executive Director [Member]

Non Executive Director [Member]

Non Executive Director [Member]

Non Executive Director [Member]

Director [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Placement Agent [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Capital Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1

'

'

'

'

'

'

'

'

'

'

'

'

28,000

'

'

5,556

8,000

'

'

'

'

'

'

'

Fair Market Value Per Common Share

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.73

$2.95

'

$4.20

'

'

'

'

'

'

'

Closing Market Price Per Common Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.17

'

'

'

$1.37

'

'

'

Share Based Compensation Number Of Share Issuable In Twelve Months Anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

'

'

'

Share Based Compensation Number Of Share Issuable In Six Months Anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

'

'

'

Common Stock Purchase Options Exercise Price

$8.11

$8.11

'

$8.11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Purchase Options Outstanding

140,000

140,000

'

140,000

'

'

247,119

247,119

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

'

'

'

442,881

11,112

5,556

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

700,000

'

'

'

'

49,000

0

'

'

10,000

2,000

'

'

'

'

'

Unrecognized Compensation Cost

'

'

'

'

'

'

$18,423

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of warrant/purchase option liability

-56,840

37,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number

'

'

'

'

'

'

144,663

86,162

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

140,000

140,000

'

'

140,000

140,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Expected to Vest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,500

'

Share-based Compensation, Total

143,549

86,162

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Total

'

$29,342

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period

62,556

24,556

'

'

'

'

70,112

7,556

'

'

'

'

7,000

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

34,230

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

114,100

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

Warrant And Right Adjusted Price Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'(number of warrants and exercise price adjusted for 1 for 10 reverse stock split on May 12, 2009 and 2 for 1 forward stock split on November 6, 2009

'

'

Class Of Warrant Or Right Expiration Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

STATUTORY_RESERVES_Details_Tex

STATUTORY RESERVES (Details Textual)	Dec. 31, 2013
Statutory Reserves [Line Items]	'
Percentage Of Net Income To Be Set Aside On Annual Basis To Statutory Surplus Reserve Fund	10.00%
Maximum Percentage Of Statutory Surplus Reserve Over Entity's Registered Capital	50.00%

TAXES_Details

TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
Current	$2,760,936	$2,168,125
Deferred	-359,628	0
Total	$2,401,308	$2,168,125

TAXES_Details_1

TAXES (Details 1)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Income Tax Disclosure [Line Items]	'		'
U.S. Statutory rate	34.00%		34.00%
Foreign income not recognized in the U.S.	-34.00%		-34.00%
China income tax rate	25.00%		25.00%
China income tax exemption	-10.00%		-10.00%
Other item (1)	3.60%	[1]	10.90%	[1]
Total provision for income taxes	18.60%		25.90%
[1]	Other items are primarily for operating expenses (income) incurred by Skystar that are not deductible (taxable) in the PRC, expenses incurred by other subsidiaries that are not deductible on the consolidated level, the difference of taxable income under US GAAP rather than Chinese GAAP, and the difference of Enterprise Income Tax imposed at a statutory rate of 25% rather than preferential tax rate of 15% on the income from the subsidiaries other than Xiban Tianxing, which resulted in an increase in the effective tax rate of 3.6% and 10.9% for the years ended December 31, 2013 and 2012, respectively. Other items consisted of the following: Years ended December 31, 2013 2012 Income taxed at Chinese statutory rate of 25% 0.2 % 4.4 % Valuation allowance on tax loss 1.5 1.8 Non-deductible operating expenses 1.9 4.7 Total other items 3.6 % 10.9 %

TAXES_Details_2

TAXES (Details 2)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Income Tax Disclosure [Line Items]	'		'
Income taxed at Chinese statutory rate of 25%	0.20%		4.40%
Valuation allowance on tax loss	1.50%		1.80%
Non-deductible operating expenses	1.90%		4.70%
Total other items	3.60%	[1]	10.90%	[1]
[1]	Other items are primarily for operating expenses (income) incurred by Skystar that are not deductible (taxable) in the PRC, expenses incurred by other subsidiaries that are not deductible on the consolidated level, the difference of taxable income under US GAAP rather than Chinese GAAP, and the difference of Enterprise Income Tax imposed at a statutory rate of 25% rather than preferential tax rate of 15% on the income from the subsidiaries other than Xiban Tianxing, which resulted in an increase in the effective tax rate of 3.6% and 10.9% for the years ended December 31, 2013 and 2012, respectively. Other items consisted of the following: Years ended December 31, 2013 2012 Income taxed at Chinese statutory rate of 25% 0.2 % 4.4 % Valuation allowance on tax loss 1.5 1.8 Non-deductible operating expenses 1.9 4.7 Total other items 3.6 % 10.9 %

TAXES_Details_3

TAXES (Details 3) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
Income taxes	$662,811	$279,680
Value added taxes	576,603	1,409,762
Other taxes	76,072	261,315
Total	$1,315,486	$1,950,757

TAXES_Details_Textual

TAXES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
Foreign Income Tax Statutory Rate	25.00%	'
Foreign Preferential Tax Rate	15.00%	'
Effective Income Tax Rate Reconciliation, Nondeductible Expense	3.60%	10.90%
Percentage Of Valuation Allowance	100.00%	100.00%
Operating Loss Carryforwards, Valuation Allowance	$1,671,817	$1,602,033
Undistributed Earnings Of Foreign Subsidiaries	50,900,000	35,600,000
Deferred Tax Assets, Net	364,425	'
Accrued Liabilities, Current	213,685	'
Allowance for Doubtful Accounts Receivable	150,560	'
U S Income Tax [Member]	'	'
Income Tax Disclosure [Line Items]	'	'
Operating Loss Carryforwards	4,917,108	4,711,862
Operating Loss Carryforwards, Limitations on Use	'These carry forwards will expire, if not utilized, beginning in 2025 and through 2033.	'
P R C Income Tax [Member]	'	'
Income Tax Disclosure [Line Items]	'	'
Operating Loss Carryforwards	4,572,233	3,467,227
Operating Loss Carryforwards, Valuation Allowance	$1,142,813	$866,807
Operating Loss Carryforwards, Limitations on Use	'These carry forwards will expire, if not utilized, through 2018.	'

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Line Items]	'	'
Net income	$10,530,252	$6,212,428
Weighted average shares used in basic computation	7,651,640	7,471,350
Effect of dilutive potential non-vested common shares	4,446	0
Weighted average shares used in diluted computation	7,656,086	7,471,350
Earnings per share:	'	'
Basic (in dollars per share)	$1.38	$0.83
Diluted (in dollars per share)	$1.37	$0.83

EARNINGS_PER_SHARE_Details_Tex

EARNINGS PER SHARE (Details Textual)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Option [Member]	'	'
Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	140,000	140,000
Non Vested Shares [Member]	'	'
Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	6,000

RELATED_PARTY_TRANSACTIONS_AND2

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
Related Party Transaction [Line Items]	'		'
Amounts due to related parties	$1,361,548		$798,925
Weibing Lu - Ceo [Member]	'		'
Related Party Transaction [Line Items]	'		'
Amounts due to related parties	857,012	[1]	608,282	[1]
Scott Cramer - Non-Executive Director And Shareholder [Member]	'		'
Related Party Transaction [Line Items]	'		'
Amounts due to related parties	300,203	[2]	138,169	[2]
Officer, Shareholder And Other Related Party [Member]	'		'
Related Party Transaction [Line Items]	'		'
Amounts due to related parties	163,050	[3]	52,210	[3]
Bing Mei Cfo [Member]	'		'
Related Party Transaction [Line Items]	'		'
Amounts due to related parties	$41,283	[2]	$264	[2]
[1]	As of December 31, 2013 and 2012, the Company had unpaid reimbursement, compensation, and advances for business expenses due to Weibing Lu valued at $857,012 and $608,282, respectively.
[2]	As of December 31, 2013 and 2012, the Company had unpaid reimbursement and compensation due to Scott Cramer valued at $300,203 and $138,169, respectively. On March 10, 2014, the Board of Directors, including all of the independent members of the Board, reviewed and approved the terms of Mr. Cramerbs Consulting Services Agreement with the Company pursuant to which the Company would continue employing him as its US representative in consideration of (i) a quarterly cash fee of $7,500, (ii) 7,000 restricted shares of the Companybs common stock issuable on a quarterly basis pursuant to the Companybs 2010 Stock Incentive Plan, and (iii) reimbursement of out of pocket expenses. In addition, Mr. Cramer agreed to pay certain invoices of the Company to its vendors (and the Company agreed to reimburse Mr. Cramer) in the form of a no interest bearing loan in the aggregate amount of approximately $250,000. As of December 31, 2013 and 2012, the Company had unpaid reimbursement and compensation due to Bing Mei valued at $41,283 and $264, respectively.
[3]	The amounts due to directors, shareholders and other related parties at December 31, 2013 and 2012 include unpaid reimbursement and advances to other related parties for business expenses.

RELATED_PARTY_TRANSACTIONS_AND3

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS (Details Textual)

12 Months Ended

3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2005

Dec. 31, 2005

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

USD ($)

Xi'an tianxing [Member]

Xi'an tianxing [Member]

Xi'an tianxing [Member]

Xi'an tianxing [Member]

Scott Cramer Non Executive Director and Shareholder [Member]

Scott Cramer Non Executive Director and Shareholder [Member]

Weibing Lu - Ceo [Member]

Weibing Lu - Ceo [Member]

Bing Mei Cfo [Member]

Bing Mei Cfo [Member]

US Representative [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Due to Related Parties, Total

'

'

'

'

'

'

$300,203

$138,169

$857,012

$608,282

$41,283

$264

'

Professional Fees

'

'

'

'

'

'

'

'

'

'

'

'

7,500

Reimbursement Payable

'

'

'

'

'

'

'

'

'

'

'

'

250,000

Capital Lease Obligations

'

'

'

'

363,414

2,220,000

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Other

437,166

'

'

'

'

'

'

'

'

'

'

'

'

Other Significant Noncash Transaction, Value of Consideration Given

'

'

$486,427

3,010,000

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period

69,556

13,556

'

'

'

'

'

'

'

'

'

'

7,000

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2013
Future Minimum Payments [Line Items]	'
Year ending December 31, 2014	$105,330
Year ending December 31, 2015	61,879
Year ending December 31, 2016	61,879
Year ending December 31, 2017 and thereafter	15,961
Total	245,049
Unrelated third parties [Member]	'
Future Minimum Payments [Line Items]	'
Year ending December 31, 2014	52,291
Year ending December 31, 2015	8,840
Year ending December 31, 2016	8,840
Year ending December 31, 2017 and thereafter	2,210
Total	72,181
Related parties [Member]	'
Future Minimum Payments [Line Items]	'
Year ending December 31, 2014	53,039
Year ending December 31, 2015	53,039
Year ending December 31, 2016	53,039
Year ending December 31, 2017 and thereafter	13,751
Total	$172,868

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details 1)

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2008

Dec. 31, 2008

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2009

Dec. 31, 2009

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

USD ($)

Project With Northwestern Agricultural Technology University [Member]

Project With Northwestern Agricultural Technology University [Member]

Project With Northwestern Agricultural Technology University [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Three [Member]

Project With Fourth Military Medical University Three [Member]

In House R And D Project One [Member]

In House R And D Project Two [Member]

In House Rand D Project Three [Member]

In House R And D Project Four [Member]

In House R and D Project Five [Member]

In House R and D Project Six [Member]

In House R and D Project Seven [Member]

In House R and D Project Eight [Member]

In House R and D Project Nine [Member]

In House R and D Project Ten [Member]

Other In House R and D Projects [Member]

USD ($)

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount incurred as of 12/31/2013

$5,360,987

$572,950

'

'

$851,240

5,200,000

'

'

$245,550

1,500,000

$50,747

310,000

$163,700

$163,700

$81,850

$81,850

$81,850

$81,850

$81,850

$409,250

$491,100

$327,400

$1,676,100

Amount expected to be incurred

785,760

81,850

654,800

4,000,000

130,960

'

982,200

6,000,000

81,850

'

0

'

0

0

0

0

0

0

0

0

81,850

392,880

16,370

Total amount of project

$6,146,747

$654,800

'

'

$982,200

'

'

'

$327,400

'

$50,747

'

$163,700

$163,700

$81,850

$81,850

$81,850

$81,850

$81,850

$409,250

$572,950

$720,280

$1,692,470

COMMITMENTS_AND_CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013
Contracted but not accrued for:	'
Purchase of machinery and construction (Note 9)	$4,358,840

COMMITMENTS_AND_CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Details Textual)

1 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Jul. 20, 2011

Apr. 15, 2011

Apr. 15, 2011

Dec. 31, 2013

7-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2008

Dec. 31, 2008

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2009

Dec. 31, 2009

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Apr. 18, 2012

Apr. 18, 2012

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Apr. 15, 2013

Apr. 15, 2013

Oct. 15, 2012

Oct. 15, 2012

Apr. 15, 2012

Apr. 15, 2012

Jul. 20, 2011

Jul. 20, 2011

Dec. 31, 2013

Dec. 31, 2013

USD ($)

CNY

USD ($)

Skystar Biotechnology (Kunshan) Co., Limited [Member]

Related Parties [Member]

Related Parties [Member]

Unrelated Third Parties [Member]

Unrelated Third Parties [Member]

Mr Weibing Lu [Member]

Mr Weibing Lu [Member]

Mr Weibing Lu [Member]

Project With Northwestern Agricultural Technology University [Member]

Project With Northwestern Agricultural Technology University [Member]

Project With Northwestern Agricultural Technology University [Member]

Project With Northwestern Agricultural Technology University [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Two [Member]

Veterinary Products Formula Adjustment Pet Drug Development and Fermentation Engineering Design and Development Project [Member]

Veterinary Products Formula Adjustment Pet Drug Development and Fermentation Engineering Design and Development Project [Member]

Jingzhou [Member]

Jingzhou [Member]

Lantian County Chicken Farm [Member]

Lantian County Chicken Farm [Member]

Lantian County Chicken Farm [Member]

Lantian County Chicken Farm [Member]

Project With Fourth Military Medical University Three [Member]

Project With Fourth Military Medical University Three [Member]

Project With Fourth Military Medical University Four [Member]

Project With Fourth Military Medical University Four [Member]

Project With Fourth Military Medical University Four [Member]

Project With Fourth Military Medical University Four [Member]

Sanqiao Factory Premises [Member]

Sanqiao Factory Premises [Member]

Shanghai Siqiangs Office Space [Member]

Shanghai Siqiangs Office Space [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Xian Warehouse Premises [Member]

Xian Warehouse Premises [Member]

Xian Warehouse Premises [Member]

Xian Warehouse Premises [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

CNY

USD ($)

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Mr Weibing Lu [Member]

Mr Weibing Lu [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of Lessee Leasing Arrangements, Operating Leases

'

'one year tenancy agreement for an office lease in Kunshan, Jiangsu Province from April 15, 2011 to April 14, 2012

'one year tenancy agreement for an office lease in Kunshan, Jiangsu Province from April 15, 2011 to April 14, 2012

'

'

'

'

'

'

'the Company renewed the lease with Mr. Lu for another 5 years from January 1, 2012 to December 31, 2016

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'tenancy agreement for the lease of a sales office in Jingzhou, Hubei Province for a period of five years from April 18, 2012 to April 17, 2017

'tenancy agreement for the lease of a sales office in Jingzhou, Hubei Province for a period of five years from April 18, 2012 to April 17, 2017

'

'

'

'

'

'

'

'

'

'

'The Company entered into a tenancy agreement for the lease of factory premises of Xi’an Tianxing in Sanqiao for a period of ten years from October 1, 2004 to December 31, 2014. The annual rent for the factory premises is subject to a 10% increase every two years starting October 1, 2009.

'The Company entered into a tenancy agreement for the lease of factory premises of Xi’an Tianxing in Sanqiao for a period of ten years from October 1, 2004 to December 31, 2014. The annual rent for the factory premises is subject to a 10% increase every two years starting October 1, 2009.

'tenancy agreement with Mr. Weibing Lu for the lease of Shanghai Siqiangs office in Shanghai for a period of ten years from August 1, 2007 to August 1, 2017

'tenancy agreement with Mr. Weibing Lu for the lease of Shanghai Siqiangs office in Shanghai for a period of ten years from August 1, 2007 to August 1, 2017

'Company entered into a another one-year tenancy agreement for this office from April 15, 2013 to April 14, 2014

'Company entered into a another one-year tenancy agreement for this office from April 15, 2013 to April 14, 2014

'Company entered into a another six-month tenancy agreement for this office from October 15, 2012 to April 14, 2013

'Company entered into a another six-month tenancy agreement for this office from October 15, 2012 to April 14, 2013

'Company entered into a six-month tenancy agreement for this office from April 15, 2012 to October 14, 2012

'Company entered into a six-month tenancy agreement for this office from April 15, 2012 to October 14, 2012

'subject to a 10% increase every two years starting July 20, 2013.

'subject to a 10% increase every two years starting July 20, 2013.

'

'

Lease Expiration Date

19-Jul-14

14-Apr-12

14-Apr-12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17-Apr-17

17-Apr-17

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14-Apr-14

14-Apr-14

14-Apr-13

14-Apr-13

14-Oct-12

14-Oct-12

'

'

'

'

Operating Leases, Rent Expense

'

$3,143

19,200

'

'

$52,342

$51,403

$79,467

$62,620

'

$29,466

180,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8,840

54,000

'

'

'

'

'

'

'

'

'

'

$22,977

140,360

$23,573

144,000

$3,853

23,536

$1,703

10,405

$1,703

10,405

$38,469

235,000

$42,316

258,500

Clinical Research Stage

'

'

'

'

'

'

'

'

'

'

'

'

572,950

3,500,000

'

'

'

'

'

'

'

'

2,000,000

327,400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount incurred as of 12/31/2013

'

'

'

5,360,987

'

'

'

'

'

'

'

'

572,950

'

'

'

851,240

5,200,000

'

'

245,550

1,500,000

'

'

'

'

'

'

327,400

2,000,000

'

'

50,747

310,000

491,100

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount expected to be incurred

'

'

'

785,760

'

'

'

'

'

'

'

'

81,850

'

654,800

4,000,000

130,960

'

982,200

6,000,000

81,850

'

'

'

1,676,100

10,238,854

'

'

'

'

720,280

4,400,000

0

'

'

'

572,950

3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment Obligation Capital

'

'

'

'

$12,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

SEGEMENT_INFORMATION_Details

SEGEMENT INFORMATION (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues	'	'
Total Revenues	$42,483,716	$33,586,791
Cost of Revenues	'	'
Total Cost of Revenues	20,992,962	15,095,004
Gross Profit	21,490,754	18,491,787
Veterinary Medications [Member]	'	'
Revenues	'	'
Total Revenues	25,515,844	10,658,359
Cost of Revenues	'	'
Total Cost of Revenues	15,181,929	6,087,300
Micro-organism [Member]	'	'
Revenues	'	'
Total Revenues	13,546,118	15,355,467
Cost of Revenues	'	'
Total Cost of Revenues	4,119,721	5,498,463
Feed Additives [Member]	'	'
Revenues	'	'
Total Revenues	1,790,981	4,021,567
Cost of Revenues	'	'
Total Cost of Revenues	1,365,794	3,074,301
Vaccines [Member]	'	'
Revenues	'	'
Total Revenues	1,630,773	3,551,398
Cost of Revenues	'	'
Total Cost of Revenues	$325,518	$434,940

PARENT_COMPANY_STATEMENTS_OF_O1

PARENT COMPANY STATEMENTS OF OPERATIONS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Condensed Income Statements, Captions [Line Items]	'	'
REVENUE, net	$42,483,716	$33,586,791
OPERATING EXPENSES:	'	'
General and administrative	3,968,984	4,746,529
Total operating expenses	8,477,890	9,940,806
LOSS FROM OPERATIONS	13,012,864	8,550,981
OTHER INCOME (EXPENSE):	'	'
Total other income (expense), net	-81,304	-170,428
Parent Company [Member]	'	'
Condensed Income Statements, Captions [Line Items]	'	'
REVENUE, net	0	0
OPERATING EXPENSES:	'	'
Salaries and consulting expenses	384,513	272,660
General and administrative	836,098	1,819,709
Total operating expenses	1,220,611	2,092,369
LOSS FROM OPERATIONS	-1,220,611	-2,092,369
OTHER INCOME (EXPENSE):	'	'
Change in fair value of purchase option liability	-56,840	37,800
Other income	0	13,819
Total other income (expense), net	-56,840	51,619
(LOSS) ATTRIBUTABLE TO PARENT COMPANY	-1,277,451	-2,040,750
EQUITY IN EARNINGS OF SUBSIDIARIES	11,807,703	8,253,178
NET INCOME AVAILABLE TO SHAREHOLDERS	$10,530,252	$6,212,428

PARENT_COMPANY_BALANCE_SHEETS_1

PARENT COMPANY BALANCE SHEETS (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CURRENT ASSETS:	'	'	'
Cash	$8,142,296	$11,321,848	'
Prepaid expenses and other current assets	2,134,163	2,839,850	'
Total current assets	88,615,112	71,652,265	'
Total assets	136,223,427	115,759,343	'
CURRENT LIABILITIES:	'	'	'
Total current liabilities	24,965,881	17,205,920	'
OTHER LIABILITIES:	'	'	'
Purchase option liability	62,440	5,600	43,400
Total liabilities	25,830,451	19,544,410	'
SHAREHOLDERS' EQUITY	110,392,976	96,214,933	88,102,813
Total liabilities and shareholders' equity	136,223,427	115,759,343	'
Parent Company [Member]	'	'	'
CURRENT ASSETS:	'	'	'
Cash	920	968	'
Prepaid expenses and other current assets	258,370	283,836	'
Total current assets	259,290	284,804	'
Interests in subsidiaries	111,331,905	96,750,650	'
Total assets	111,591,195	97,035,454	'
CURRENT LIABILITIES:	'	'	'
Accounts payable and accrued expenses	120,720	126,062	'
Salary and consulting fees payable	71,972	71,838	'
Due to related parties	943,087	617,021	'
Total current liabilities	1,135,779	814,921	'
OTHER LIABILITIES:	'	'	'
Purchase option liability	62,440	5,600	'
Total liabilities	1,198,219	820,521	'
SHAREHOLDERS' EQUITY	110,392,976	96,214,933	'
Total liabilities and shareholders' equity	$111,591,195	$97,035,454	'

PARENT_COMPANY_STATEMENTS_OF_C1

PARENT COMPANY STATEMENTS OF CASH FLOWS (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income available to shareholders	$10,530,252	$6,212,428
Adjustments to reconcile net income to net cash used in operating activities:	'	'
Common stock to be issued to related parties for compensation	143,549	86,162
Change in fair value of purchase option liability	56,840	-37,800
Change in operating assets and liabilities	'	'
Prepaid expenses and other current assets	763,031	1,651,478
Net cash used in operating activities	-5,423,380	6,546,259
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Net cash provided by investing activities	-2,585,501	-544,950
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Net cash provided by financing activities	4,684,950	-1,713,420
DECREASE IN CASH	-3,179,552	4,272,880
CASH, beginning of year	11,321,848	7,048,968
CASH, end of period	8,142,296	11,321,848
Parent Company [Member]	'	'
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income available to shareholders	10,530,252	6,212,428
Adjustments to reconcile net income to net cash used in operating activities:	'	'
Equity in earnings of subsidiaries	-11,807,703	-8,253,178
Common stock to be issued to related parties for compensation	143,549	86,162
Common stock issued under 2010 stock incentive plan	0	1,037,911
Change in fair value of purchase option liability	56,840	-37,800
Change in operating assets and liabilities	'	'
Prepaid expenses and other current assets	25,466	-27,836
Accounts payable and accrued expenses	-5,342	-401,077
Salary and consulting fees payable	134	-273,050
Increase in due to related parties	565,496	326,630
Net cash used in operating activities	-491,308	-1,329,810
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Decrease in interest in subsidiaries	491,260	1,318,270
Net cash provided by investing activities	491,260	1,318,270
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Net cash provided by financing activities	0	0
DECREASE IN CASH	-48	-11,540
CASH, beginning of year	968	12,508
CASH, end of period	$920	$968